Because of the key role played by the body's lean tissue reserves (of which skeletal muscle is a major component) in the response to injury and illness, its maintenance is of central importance to nutrition status. With the recent development of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition diagnostic framework for malnutrition, the loss of muscle mass has been recognized as one of the defining criteria. Objective methods to evaluate muscle loss in individuals with acute and chronic illness are needed. Bioimpedance and ultrasound techniques are currently the best options for the clinical setting; however, additional research is needed to investigate how best to optimize measurements and minimize error and to establish if these techniques (and which specific approaches) can uniquely contribute to the assessment of malnutrition, beyond more subjective evaluation methods. In this tutorial, key concepts and statistical methods used in the validation of bedside methods to assess lean tissue compartments are discussed. Body composition assessment methods that are most widely available for practice and research in the clinical setting are presented, and clinical cases are used to illustrate how the clinician might use bioimpedance and/or ultrasound as a tool to assess nutrition status at the bedside. Future research needs regarding malnutrition assessment are identified. (JPEN J Parenter Enteral Nutr. 2015;39:787-822) Keywords body cell mass; nutrition status; malnutrition; fat-free mass; lean body mass; muscle mass; muscle loss; skeletal muscle; intracellular water; bioimpedance; spectroscopy; impedance ratio; phase angle 
Tutorial
There has been long-standing interest in the assessment of lean tissue as a key parameter of nutrition status. Specifically, lean tissue mass (of which skeletal muscle is a major component) plays a central role in the body's ability to respond to acute and chronic illness by serving as a vitally important reservoir of amino acids that can be redirected to the tasks of injury repair and the immune response when needed.
1,2 Albeit highly functional, the process of protein catabolism under these circumstances leads to loss of lean tissue. The loss of lean tissue and overt sarcopenia (defined as loss of muscle mass and strength 3 ) that often occur in the face of chronic and acute illness carry significant ramifications in terms of clinical outcomes, including increased incidence of infections, 4, 5 increased length of stay, 6 and increased morbidity and mortality. [7] [8] [9] Indeed, we now have published cutpoints defining sarcopenia by several body composition assessment methods (see Table 1 ) [10] [11] [12] [13] ; these are also used as part of the defining characteristics of cachexia, a term used to describe the significant weight loss, protein catabolism, and muscle and fat tissue loss that occur due to underlying disease processes.
14 Furthermore, with the recent publication of the Academy of Nutrition and Dietetics (AND)/American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) consensus statement 15 defining diagnostic criteria for malnutrition, there has been renewed focus on the assessment of muscle loss as a key component of nutrition status. As the consensus malnutrition diagnostic framework has been developed, much attention has been paid to the assessment of muscle loss through physical examination techniques 16 ; however, the subjective nature of physical examination is a potential limitation. One of the major limitations of any subjective method is poor reliability due to interobserver and intraobserver variability. Although intensive and standardized training programs may be able to minimize that variability, the potential for error remains high as the technique is broadly applied across medical centers. Furthermore, lean tissue loss can precede overt weight loss 17 and may be masked by excess extracellular water (ECW), 18 thus making it difficult to detect through visual techniques. A recent 595227P ENXXX10.1177/0148607115595227Journal of Parenteral and Enteral NutritionEarthman research-article2015 article by Sheean et al 19 would attest to this. They reported that 60% of individuals with respiratory failure who were deemed normally nourished at intensive care unit (ICU) admission by subjective global assessment 20 (administered by experienced clinicians) were actually sarcopenic as defined by computerized tomography (CT). Approximately 33% of individuals who were misclassified were overweight or obese. Although there is no clear consensus yet on how best to define and identify it, 21 ,22 the problem of sarcopenia in the presence of obesity has significant clinical implications. 7, 9, 23 For all these reasons, a method to objectively and reliably evaluate lean tissue loss at the bedside is highly desirable but has been somewhat elusive.
In the first part of this tutorial, basic terminology around the assessment of lean tissue body composition is introduced. In the second part, key concepts around validity of field (which we will henceforward term bedside) techniques, as they compare with reference methods, are presented. Subsequently, the statistical methods that are typically used in the validation of bedside techniques are reviewed to gain perspective on the interpretation and application of the research literature. In the third and fourth parts, body composition assessment methods that are most widely available for practice and research in the clinical setting are subsequently discussed, including multiple dilution, dual-energy X-ray absorptiometry (DXA), and CT (reference methods), as well as bioimpedance and ultrasound (bedside methods). In the fifth part, clinical cases are used to illustrate how the clinician might ultimately use bioimpedance and ultrasound to assess lean tissue and/or nutrition status at the bedside. Finally, the sixth part addresses gaps in the research literature around malnutrition assessment where additional clinical research studies are needed.
Introduction to Lean Tissue Terminology
Multiple terms to describe the lean tissue compartment of the body, based on various conceptual models of body composition, have been well described elsewhere. 24, 25 At the most basic level, the 2-component model of body composition describes the body as the sum of fat mass and fat-free mass (FFM) . FFM thus is a rather broad term that includes skeletal muscle, nonskeletal muscle, organs, connective tissue, total body water (TBW, including ECW and intracellular water [ICW] ), and bone. FFM can be estimated from TBW measurements using the following equation: This hydration constant has been shown to be remarkably stable under euhydrated, healthy conditions 26 but varies under clinical conditions where hydration may be altered and has been shown to be somewhat higher (>0.75) in individuals with extreme obesity. 27, 28 The lean body mass (LBM), which is more appropriately termed lean soft tissue (LST) when measured by DXA, is a slightly more specific compartment that includes all of the aforementioned components except for bone. 29 The body cell mass (BCM) is a term originally described by Moore and Boyden 30 as the total mass of cells in the body that consume oxygen and produce work; it is the nonfat cellular portion of tissues, of which the primary components are skeletal muscle, organ tissue mass, blood, and the brain. 31 As such, the BCM has been considered by many to be the primary lean tissue compartment to assess nutrition status and to serve as a key target for nutrition interventions. 32, 33 There is no direct way to quantify BCM, but there are several ways it can be estimated, including from total body nitrogen determined by neutron activation analysis (NAA), total body potassium through total body potassium counting (TBK), and ICW measured by multiple dilution. 30, 32, [34] [35] [36] Given that NAA exposes individuals to radiation, and both NAA and TBK are highly technical and expensive, ICW through multiple dilution is one of the more accessible reference methods to clinical researchers and depends on the underlying observations that a large proportion of the BCM is represented by the water content of cells, and acute changes in body protein occur primarily within cells, and these changes are generally accompanied by changes in ICW. 37, 38 Nevertheless, despite differences in their level of specificity to core functional processes, all of the aforementioned lean tissue compartments, including FFM, LST, and BCM (and/or ICW itself), may be measured as the target variable in methods validation, as well as nutrition assessment and intervention studies, depending on the available body composition assessment methods.
Validation of Bedside Techniques to Assess Lean Tissue in Clinical Settings
Several excellent reviews describe the various methods that are available to evaluate lean tissue compartments. 29, 39, 40 Bedside techniques need to be validated against more established reference techniques before they can be applied with confidence in the clinical setting. It should be noted that all methods to evaluate body composition are indirect, requiring various assumptions that may or may not hold true in acute and/or chronic illness, and none is completely free from error. Thus, the term gold standard, which has been used in the past, has been replaced with the term reference to describe the more established techniques against which bedside methods are validated. For the purposes of this discussion, the focus is primarily on bioimpedance and ultrasound techniques as 2 promising currently available bedside assessment options. The most common reference methods against which bioimpedance and ultrasound have been compared in clinical studies include multiple dilution, DXA, and CT. Although magnetic resonance imaging (MRI) is also an important reference method for validation studies, it is generally less widely available to clinician researchers and thus will not be discussed in this tutorial. However, the reader is referred to a recent review that includes discussion of MRI. 29 Before these methods are briefly described, however, it is important to understand the key terminology and statistical approaches used in methods validation.
Basic Terminology Regarding Validity
There are several important concepts to keep in mind as we talk about the validation of bedside methods. At the heart of it, the effort to prove the validity of a bedside method is undertaken to establish that method as an acceptable alternative to a more expensive and/or technical and, usually, less widely available technique. Theoretically speaking, the definition of validity is the extent to which a measurement actually measures the "true" value of a particular body composition parameter; however, given that the "true" quantification of body composition components may only be known through cadaver analysis, and there are no completely error-free "gold standards" among body composition assessment methods applied to living humans, it is virtually impossible to determine that "true" value. The best we can do is to compare the bedside method with the best reference method that is available to measure the compartment of interest, and if the methods produce sufficiently comparable measures with acceptable measurement error, we can then call the bedside method valid. Thus, in most of the body composition literature, the term validity is used more generally and encompasses such concepts as precision, bias, and accuracy, among others. In general, measurement error can be conceived of as falling into 1 of 2 categories: (1) random error due to biological variation and other factors and (2) systematic error that occurs from constant fixed and/or proportional bias. From a practical standpoint, investigators aiming to validate a device or technique should strive to evaluate (1) how close do the values obtained by the bedside method agree with the values obtained by the reference method, (2) how often are the values within an acceptable range of difference, and (3) whether there is a consistent tendency for the bedside method to over-or underestimate the body composition compartment of interest compared with the reference method. To answer these questions, it is important to know the precision of the reference method and to evaluate the precision, accuracy, and bias of the bedside method.
Precision and reliability. The term precision as it applies to body composition measurement is typically used to describe the degree of agreement among repeated measurements by a particular assessment method (ie, how well does a particular method produce the same result on multiple occasions). There is another use of the word that is sometimes seen in the literature, although it deviates from the true definition; precision is sometimes loosely used to describe how well a bedside technique produces measurements sufficiently close to those produced by a reference method in a group of individuals (ie, how variable are individual measures between methods, defined in part by the limits of agreement or 95% confidence interval, which will be discussed later) but not necessarily taking into consideration inter-or intraobserver errors that would typically be used to describe precision in terms of repeatability and reproducibility. We will assume the first definition when precision is discussed and will indicate when the alternative meaning is intended by using "precision." Reliability is a term that is used to describe a method that is considered to have high precision. Random error will affect the precision and reliability of a method. 41 For a method to be considered reliable, it should have high repeatability and reproducibility. Repeatability is a term that refers to the variability between repeated, independent measurements of a particular variable (eg, FFM) that are made by the same operator or observer using a single device, in the same individual, under the same conditions. Reproducibility, on the other hand, can be used to describe the variability in measurements of a particular variable taken by that particular device operated by different observers in the same institution or in different institutions. Imprecision has been defined as the variability of repeated measurements due to intra-and interobserver measurement differences. 42 Interobserver measurement error (ME) refers to the variability in a particular variable by the same method when measurements are made by more than one operator. Intraobserver ME refers to the variability in a particular variable by the same method when more than one measurement is made by the same operator. ME is typically referred to as technical error in the anthropometric literature. 42 To calculate intraobserver ME for 2 measurements and interobserver ME for 2 operators, the same equation may be used 42 : Because ME can sometimes be positively associated with the size of measurement, it is advantageous to convert the absolute ME to a relative ME term, which can be done by calculating the %ME using the following formula 42 : ME mean of measurements / ( ) ×100.
Calculating the %ME in this way is a variation on the measurement of the coefficient of variation (CV), which is typically calculated by dividing the standard deviation (SD) by the mean of the set of measurements and then converting to a percent (ie, CV = SD/mean × 100). In fact, it could be said that all expressions of error are ideally described as a percentage relative to the actual size of the compartment being measured, although it is important to remember that there will be differences in relative magnitude between various error terms. A method that is subject to high inter-and intraobserver errors is judged to have low precision. Simple anthropometry using skinfolds and circumferences is an example of a method that has been shown to have low precision, with %ME approaching 8% and CVs as high as 45% for some skinfold measurements. [42] [43] [44] To summarize, random error (caused by biological variability, as well as errors in the measurement procedure caused by protocol deviations, random instrument error, operator error, and environment, among other factors) as it relates to precision can be expressed in several different ways, but the bottom line is we are attempting to capture the degree of variability in measurements not due to fixed systematic error. You will see derivations of the same concept applied to calculate other error terms as we go along, with minor adjustments to the formulae depending on the statistical approach. Statistical terms that are commonly used to describe reliability and precision include test-retest correlation coefficients (same day or between day), intraclass correlation coefficient (ICC), SD, and CV for a given set of measurements. ICC values approaching 1.0 would indicate low variability between repeated measures of the same subject (ie, low ME). Root mean squared error (RMSE) can also be calculated to estimate random error in a bedside method, and although there are slight deviations that might be applied when using multiple regression analysis, 45 RMSE (sometimes termed pure error) can be calculated as follows 46 : RMSE = n where is the reference
, , is the bedside measure, and n is the number of subjec X t ts measured.
Accuracy and bias.
The term accuracy is used to indicate the closeness of agreement in a particular variable between 2 assessment methods (ie, how close are the values of a particular variable by a bedside method to those generated by an accepted reference method). The term bias is a general term to describe the systematic error in a method (ie, the difference between the measurements made by the bedside method and those made by the reference method). Bias is typically calculated as the mean of the differences in a particular measurement variable between the 2 methods being compared. Fixed (or constant) bias refers to the type of systematic error that occurs when a method yields measurements of a particular variable that are consistently higher or lower than those taken by the reference method. The method can be highly precise in terms of repeatability and reproducibility yet still yields values that are predictably and consistently lower or higher than those made by a reference method (ie, low accuracy). For example, a single-frequency bioelectrical impedance analysis (SF-BIA) device shown to have high precision can be used to generate data applied to an equation that might have been developed from deuterium dilution data to predict TBW; when that equation-generated TBW value is converted to FFM using standard assumptions (eg, TBW/0.73 = FFM) and those values are subsequently compared with FFM values generated by DXA, it can lead to a type of fixed constant bias (ie, systematic error) termed scaling error. In this case of high precision but low accuracy, it is possible that the fixed bias might be addressed through the use of a correction factor. Unfortunately, errors between methods are rarely that simple to address. Proportional or positional bias refers to errors that are proportional to the value of the variable being measured. An example of this type of error is the proportional bias observed in bioimpedance measurements of lean tissue in individuals with extreme obesity. The errors in ICW and other lean tissue compartments by all bioimpedance techniques have been well demonstrated to increase with increasing adiposity. [47] [48] [49] Thus, the accuracy of a single measurement in a single individual is impossible to ascertain with 100% certainty, but it may be inferred from estimates of the precision of the method as well as from an understanding of the systematic error of the method.
In methods validation, there are 2 primary ways of thinking about accuracy, in part based on the statistical methods used to evaluate it. The first school of thought would argue that a bedside method is accurate if the average of all measurements taken by that method is close to the average of all measurements taken by the reference method (ie, the mean difference between methods is close to 0); the closeness of agreement between methods at the individual level is not taken into consideration. In this line of reasoning, the primary concern is that a method has low bias (ie, a method could have low precision and individual values by the 2 methods could be quite different, and the method could still be called accurate as long as low bias at the mean level is evident). An example of when this definition of accuracy is most commonly (and probably appropriately) applied is in large-scale epidemiologic studies that compare measurements of a variable (eg, FFM) by a field method such as bioimpedance with a reference method such as DXA, in order to establish bioimpedance as an acceptable method for describing population-level mean differences in FFM across different ethnic groups. The statistical approaches used to establish accuracy based on this definition include correlation and paired t test statistics. We will revisit these methods in the following sections.
The second school of thought would argue that a technique cannot be considered accurate unless measurements of a particular variable by 2 methods agree closely with one another across all individuals. The statistical approach typically used to establish accuracy based on this definition is Bland-Altman analysis, including calculations of various error terms and limits of agreement (defined as mean difference between methods ±1.96 SD) that can help us to determine if a method is truly acceptable to replace another more established method for the individual at the bedside. There are no clear guidelines on what should be considered an acceptable range for the limits of agreement to define a method as valid. It is up to the individual conducting the study to determine what defines acceptable in terms of the width of the limits of agreement. Therein lay one of several difficulties in the interpretation of validation studies. We will get back to Bland-Altman analysis and its application and interpretation in a subsequent section.
Sensitivity and specificity.
Although not typically used to describe methods comparisons, for our purposes, it is useful to review what is intended by the terms sensitivity and specificity, particularly as they pertain to the identification of malnutrition by a particular technique. Sensitivity can be defined as the percentage of truly malnourished individuals who are correctly identified as such, calculated as follows: If a body composition assessment technique is to be useful to identify individuals with malnutrition, it will need to have high sensitivity and specificity (>90%, ideally-particularly for sensitivity). 51 
Statistical Techniques Used to Evaluate Agreement Between Methods in Validation Studies
Multiple statistical approaches can be applied to the problem of establishing the validity of a particular bedside method compared with a reference method. It is highly recommended that a combination of approaches be used to evaluate both meanlevel and individual-level agreement. Regression and correlation analyses and paired t tests are the most commonly applied statistical approaches used to evaluate agreement between 2 body composition assessment methods in terms of mean-level agreement.
Regression analysis. Simple linear regression and correlation analyses are statistical approaches that have traditionally been used to evaluate the relationship between 2 different (eg, bedside and reference) body composition assessment methods as a way of validating the bedside technique. While correlation analysis simply tells us the strength of the interrelatedness of 2 sets of data, linear regression evaluates the nature of the relationship. 52 A strong linear relationship and high correlation between 2 sets of data may be interpreted to mean "good agreement" between methods, although this conclusion may be faulty. To use linear regression analysis on a set of data, several underlying assumptions should be met, including normal distribution of the continuous variable data, among others. Typically, measurements of a body composition compartment (eg, TBW) by a bedside method (eg, an SF-BIA equation) are regressed against those measured by a reference method (eg, deuterium dilution) to create a least squares regression line describing the relationship between the 2 methods, reflected by the general equation y = mx + c, where m is the slope of the line and c is the intercept (ie, the value of y when x is 0). The 45° line of identity (or line of equality) is used to represent perfect unity and can be represented by the equation y = x, where the slope is 1 and the line goes through the origin.
For the purpose of illustration, Figure 1 represents various scenarios resulting from linear regression analyses applied to body composition data. Plots A and C of Figure 1 show the regression line to be very close to the line of identity, when a bedside method is either highly precise and unbiased (A) or not very precise but unbiased (C). However, you would not usually expect the regression line (Y on X) to go through the origin and have a slope of 1; in fact, more commonly, measurement errors in X will reduce the slope of the line, such that the slope will be <1, and the intercept will be >0. The correlation coefficient (eg, the Pearson product-moment correlation coefficient), referred to as r (along with the P value indicating statistical significance), is used to reflect the strength of the association between the 2 methods compared with the line of identity. 41 Interpretation varies depending on the application 53 ; the closer the r value is to 1.0 (+1 or -1), the stronger the association (positive or negative, respectively), with values in the range of 0.9-1.0 typically interpreted as strong and values <0.50 interpreted as weak associations between body composition methods. Squaring r to get the coefficient of determination (R 2 ) is useful, in that it can be interpreted directly as the percentage of variation in the measurements by one method that is related to the variation in the other. 53, 54 For example, an r of 0.99 would yield an R 2 value of 0.98, which could be interpreted as "98% of the variation in TBW predicted by the SF-BIA equation is related to the variation in TBW measured by deuterium dilution"; such a high value for r and R 2 could further be interpreted to suggest that the BIA approach might be considered a valid way to estimate TBW, although other considerations should be made before that conclusion is drawn. For example, the degree of error in the measurement needs to be evaluated. How far the measurements plotted on the y-axis vary around the regression line is typically described as the degree of error and may be represented by the term standard error of the estimate (SEE). SEE can be calculated by taking the square root of the sum of the squared differences between measured and predicted values divided by n, the number of pairs of scores, minus 2; this is represented by a very similar equation to that used to compute RMSE 55 :
It is also useful to evaluate SEE for a bedside method in terms of percentage error compared with the mean body composition compartment measurement by the reference method; for example, if we were comparing FFM measured by an SF-BIA approach against DXA, we would calculate SEE/ mean FFM by DXA 100
Linear regression analysis has been criticized as a poor approach to establish the validity of a body composition assessment method, due to several inherent methodological limitations, and if used as the sole method to evaluate agreement between methods, it will more often than not lead to faulty conclusions. For example, if you have a high degree of heterogeneity and low precision in your sample, it is quite easy to obtain a high value of r. 56 On the other hand, highly precise, homogeneous data generated by a bedside method can also yield a high value of r, despite having substantial systematic error (eg, high bias). 57 The reader is again referred to Figure 1 , which can further illustrate some of these points, based on hypothetical FFM data generated by a bioimpedance technique and a DXA instrument. If the bioimpedance method is highly precise and unbiased, the regression line for the relationship between that method and DXA might appear as shown in Figure 1A , with a statistically significant (P < .05) and very high value for r and R 2 . On the other hand, the bioimpedance method might be highly precise but significantly biased (see Figure 1B) , and you could still have a strong correlation signified by a high value for r and R 2 with a high degree of statistical significance. Such a situation can easily arise, as you can imagine when you look at 2 data sets that differ in value by 50% (eg, {1,2,3,4,5,6} and {2,4,6,8,10,12}); comparison of these data by linear regression would yield a perfect correlation of 1 and an SEE of 0, despite the significant bias present. Figure 1C illustrates a highly imprecise method that produces values that on average are unbiased compared with the average of the values produced by DXA. This kind of result would meet our first definition of accuracy based on mean-level agreement but, due to the imprecision of the method, would not meet our second definition of accuracy based on individuallevel agreement. Yet another possibility, illustrated in Figure  1D , can be seen when a bedside method is both imprecise and highly biased; in this case, the poor agreement between methods would be reflected by a low correlation coefficient.
The commonly applied least squares linear regression approach is partly based on the assumption that the reference method has minimal error compared with the range of the measurements. Given that there is error in both reference and bedside methods, this assumption may be faulty. Orthogonal least squares regression (eg, Deming regression 58, 59 or Passing-Bablok regression [59] [60] [61] [62] [63] ) assumes measurement errors are produced by both methods and are independent and normally distributed; this approach has been advocated as an alternative 58, 64, 65 but has not yet been widely applied in the body composition assessment field. Finally, concordance correlation coefficient (CCC) and ICC (which is sometimes applied to evaluate precision, as mentioned earlier) analyses have been advocated as superior to simple linear regression analyses, because they yield a value approaching 1.0 only if there is minimal bias and the paired measurements are in close agreement. Thus, the CCC not only provides a measure of association between method variables but also indicates how close values are to the line of identity. Although CCC has been advocated to be superior to Pearson's product-moment correlation because it considers both systematic and random error, [66] [67] [68] it has also been criticized for relying on similar assumptions to those underlying Pearson's correlation, such that highly heterogeneous and low precision data can lead to high r values and erroneous interpretation as good agreement between methods. 56 That said, there may be occasions when some form of regression analysis is the only procedure that can reasonably be applied to 2 sets of data. The particular example that comes to mind is when one is attempting to validate a method that measures a distinctly different lean tissue compartment from that measured by a reference method (eg, ultrasound measures of the upper quadriceps muscle compared with LST measures by DXA). It would be impossible to compare these directly, given the magnitude of difference between them, but a strong correlation would suggest that there might be utility in the ultrasound measures, particularly if the SEE were relatively small. In this validation scenario, it would be recommended to take longitudinal measures to ascertain measures of change in the compartment of interest, assuming that relatively high precision and reliability (ie, minimal random error) in the bedside assessment method could be achieved. Strong correlation between measures of change in this case could be interpreted as good agreement between the techniques. Another situation that frequently arises in the nutrition assessment field is the evaluation of a variable or set of variables for the ability to identify malnutrition. For example, in the bioimpedance field, select raw data parameters have been evaluated for their ability to identify malnutrition. The only way that this kind of relationship can be established is through the use of regression analysis, most commonly taking a multivariate approach. Nevertheless, in most instances, it is not recommended to rely solely on the evaluation of the linear association between methods but rather to use a combination of techniques to evaluate both mean-level and individual-level agreement. Although analysis of variance (ANOVA) techniques would be most appropriate when comparing more than 2 methods, our focus here is on the comparison of two, a bedside method to a reference method, and thus, ANOVA will not be discussed. Paired t test is another procedure that is frequently used to determine mean-level agreement between a bedside and reference method.
Paired t test. The paired t test procedure can be used to test the difference between the means of 2 sets of measurements on each of a group of individuals. Put simply, the difference between each set of measurements is computed, and the test is applied to determine whether the mean difference is significantly different from zero. Because you are essentially testing the null hypothesis that the 2 sets of data produce equal means, achieving statistical significance for this test is interpreted as "the 2 methods do not produce equivalent values." If, on the other hand, statistical significance is not reached, and thus the null hypothesis is not rejected, the conclusion cannot be assumed to be that there is no difference between the methods, only that no difference could be found. The statistical significance level (α) is typically set at 0.05, and the 95% confidence interval of the differences between the methods (defined as the mean difference ±1.96 SD) is calculated in the procedure. If the 95% confidence interval of the differences excludes zero as a possibility, then we conclude that bias is present in the method, and the null hypothesis is rejected (P < .05). On the other hand, if zero is included in the 95% confidence interval, the null hypothesis is not rejected (P > .05), and it might be concluded that the methods are not different, although this could be an erroneous conclusion.
A major limitation of using the paired t test to compare a bedside method with a reference method for agreement is that the results are quite difficult to interpret. For example, if statistical significance is reached when a paired t test is conducted, the finding of difference between methods could be due to random and/or systematic error. It would be impossible to ascertain which of these (and to what magnitude) is primarily in evidence. Furthermore, a nonsignificant result from a paired t test can easily occur when there is equally distributed imprecision in a set of measurements, with both negative and positive intermethod differences; these differences will cancel each other out when averages are compared, and the mean will appear to be close to zero. In fact, one conservative approach to method comparisons, particularly with small sample sizes, is to set statistical significance (α) at .10 rather than the typical .05. One might choose to do this to minimize the possibility of making a type II error (ie, to avoid the error of falsely accepting the null hypothesis of no difference between the 2 methods). 49 One reasonable approach to minimize erroneous conclusions from a paired t test is to apply it in combination with linear regression and correlation analyses; a high degree of correlation and a highly nonsignificant P value for the paired t test would suggest good agreement (at least at the mean level) between methods. However, to ascertain fixed and proportional bias (ie, systematic error), as well as the level of agreement on the individual level, it is advisable to take additional steps, including analysis of the data as recommended by Bland and Altman. 57, 69, 70 Bland-Altman analysis. Although it is not the only methodologic approach that may be taken and is not universally advocated, 71, 72 Bland and Altman's seminal paper in 1986 70 proposing their method of plotting the differences between values generated by 2 methods of measurement on the y-axis against the average of the values produced by the 2 methods on the x-axis is considered by many to be important to the body composition assessment field. They did not invent the method, but they advocated its application to the comparison of medical devices, laboratory tests, and other clinical techniques to ascertain bias in one method compared with another. One of the strengths of the Bland-Altman approach is that by calculating the mean of values measured by the 2 methods, there is recognition that there is random error associated with both methods (ie, the reference method is not infallible and thus is not a true "gold standard"). The Bland-Altman method can also be used to evaluate agreement between replicate measurements by one method, but this will not be discussed here. When using BlandAltman plots to evaluate agreement between 2 methods, the mean values by the 2 methods are usually plotted on the x-axis. On the y-axis, the values for the difference between methods in the body composition parameter are typically plotted, but difference may also be expressed as a percentage of the mean body composition parameter values (either the mean value from both methods or the mean value by the reference method). Figure 2 provides a series of Bland-Altman plots that might be constructed based on different hypothetical sets of FFM data generated by an SF-BIA equation and DXA. The first step in the process is to construct a scatterplot of the differences between methods (y) against the averages between methods (x). The next step is to take the mean difference (ie, bias) between methods and calculate the limits of agreement around the bias. This is done by calculating the mean ± 1.96 SD for the differences between the methods and drawing a horizontal line corresponding to the mean, to the value at the mean + 1.96 SD, and to the value at the mean -1.96 SD. Assuming a normal distribution, the limits of agreement should encompass 95% of all measured values; the width of the limits of agreement has been described by the word "precision" based on the alternative definition of the word discussed earlier. 73 Bland and Altman talked about how to calculate confidence intervals and SD for the limits of agreement as a way of evaluating the "precision" of those estimates, but that is beyond our discussion here.
A major criticism of the Bland-Altman technique is that the decision to accept the new technique, or, in our case, the bedside method as an acceptable alternative to the reference technique, is left entirely up to the subjective judgment of the evaluator. The ideal bedside method would demonstrate narrow limits of agreement, around a mean bias of zero. This is demonstrated in Figure 2A . Far more common, particularly when it comes to bioimpedance techniques compared with dilution reference methods, is to observe wide limits of agreement (see Figure 2B ) when applying the methods in various clinical populations. Another important step is to determine if the differences are significantly correlated with the averages. If there is a significant correlation, then there is proportional bias. This can be seen in the example shown in Figure 2C . If, on the other hand, there is no significant correlation but the mean difference between methods is consistently and significantly less than or greater than zero, suggesting that the bedside method consistently produces underestimates or overestimates of the measured variable compared with the reference method, then fixed bias is evident (see Figure 2D ).
The Bland-Altman method has recently been criticized, and suggestions have been made on how to optimize its application and interpretation. [74] [75] [76] [77] Ludbrook 74 proposed that after plotting the differences against the averages, the next step is to evaluate if the differences are correlated with the averages and, if the P value is not statistically significant for r, then proceed with calculating the standard 95% limits of agreement. If, on the other hand, the averages and differences are significantly correlated, then proportional bias is evident and hyperbolic 95% prediction limits can be calculated. These recommendations hold if the scatter of differences is uniformly distributed across the range of averages. The reader is referred to the article by Ludbrook 74 for additional information on what to do if the scatter of differences increases with the values of the averages and other contingencies.
One of the major problems in method comparisons is that both the bedside and reference techniques have a certain degree of random error associated with them. Even the most precise methods have some degree of error. The Bland-Altman approach is good, in that calculating the average between the 2 methods allows for relatively equal weighting between the 2 methods. However, as stated previously, it is up to the clinician to judge whether the limits of agreement are sufficiently narrow to allow for the bedside method to replace the reference method. To truly answer that question, it is important to consider the precision of both the reference and the bedside method. Bland and Altman 57 described the importance of having at least 2 measurements by a particular method on each subject, so that the repeatability coefficient (ie, precision) for the method could be calculated from the SD of the differences between pairs of those repeated measurements, reflected by the equation 2 × SD. They described the repeatability coefficient as the "difference that will be exceeded by only 5% of pairs of measurements on the same subject." 57 This would allow for evaluating not only the limits of agreement between the 2 methods but also the repeatability (ie, precision) for each method separately. Repeated measures are not always obtained in studies; Ward 75 recently provided a thought-provoking illustration of how a modified version of that approach might be used when repeated measures are not available to better define the validity of a method, building from a method described for techniques to measure cardiac output. 76, 77 These authors advocated for the calculation of the percentage error (PE) of the limits of agreement compared with the mean of the measurements as a way of defining a cutoff for acceptability of a method. In this approach, the "precision" of a method is defined to be 1.96 (or for simplicity, rounded to 2) times the CV for that method. Note that the use of the word "precision" here is not the traditional definition based on CV for repeatability and reproducibility but rather the alternate definition based on the spread of the individual data from the BlandAltman analysis. Using the Bland-Altman plot shown in Figure  2B , we can see how we might reevaluate a hypothetical set of validation data. To do this, we will need to make an assumption that the precision of the DXA was actually determined from repeat measures to get a CV of 2%. We will also assume that we do not have repeat measures by our SF-BIA method, and thus, we can follow the recommended steps to calculate the "precision" of the SF-BIA equation as follows 75 : CV CV CV which can be rear
r ranged to yield
w which can be rearranged to yield is rather h high and would be considered unacceptable .
Of course, had we not gone through these steps, we might have come to the same conclusion-namely, that the wide limits of agreement reflected too great a variability at the individual level; however, if our reference method had worse precision, say, a CV of 10%, then we may have deemed a 17% "precision" in our bedside method to be acceptable. If, on the other hand, we look at the data in Figure 2A , making the same assumptions about the precision of the DXA reference (still 4) and the mean of the FFM values by the 2 methods (still 32 kg), then using the limits of agreement of 1.0, we can calculate the PE to be 1.8/32 = 5.6%, and then "precision" of the SF-BIA in this case would be √(5.6) 2 -(4) 2 = 3.9%; this would obviously be considered quite good. To reiterate Ward's point, this is not to say that this approach should be adopted as standard but rather to suggest another way to look at limits of agreement in light of the reference method precision. 75 Furthermore, the decision as to what degree of "precision" can be considered clinically acceptable is likely to vary depending on the application.
A 10% CV may be acceptable for a population-based study but may not be acceptable for individual bedside monitoring; there is not yet consensus regarding this point.
Hopefully, it is clear from these illustrations that it is important to keep in mind the precision of the reference method against which your bedside method is being compared. It is advantageous for the reference technique to be as accurate and precise as possible and for the precision of the reference technique to be measured within the same study, although logistical constraints may make that difficult to achieve, depending on the method. Although there is no consensus on this, it may be suggested that for clinical utility for bedside assessment and monitoring, a PE between reference and bedside methods of 10%, with an estimated "precision" for the bedside method that comes within 10% of the precision of the reference technique, could be considered acceptable for absolute whole-body estimates. If, on the other hand, we are attempting to measure longitudinal changes in whole-body estimates, to have confidence in our measures, we would want the percent error in our bedside (and reference) methods to be less than the expected percent change in the body composition variable.
Measuring Longitudinal Changes as a Way of Validating a Bedside Method
In many ways, for a method to be useful in the clinical setting, it is most critical to establish a method's ability to detect changes over time. In fact, the evaluation of a bedside method's ability to measure longitudinal changes in individuals who are undergoing a stimulus to induce anabolic or catabolic changes in lean tissue is an important way to validate it; furthermore, the measurement of changes can help to mitigate the problem of scaling differences (ie, fixed constant bias or systematic error) between methods. Two excellent examples of opportunities to do this include individuals undergoing cancer treatment who are likely to exhibit lean tissue wasting or individuals undergoing anabolic therapy to treat wasting in human immunodeficiency virus (HIV) infection. Obviously, the ability to measure changes in lean tissue is of fundamental importance to the clinician wishing to monitor a patient's response to a nutrition intervention or simply to monitor nutrition status while the patient undergoes various medical therapies during a hospital stay. The clinician wants to have confidence that the bedside method is sufficiently sensitive to provide meaningful information about lean tissue changes. To achieve that, measures of change by the bedside method must be sufficiently close in value to those measured by the reference method to establish the method's validity. If the reference method against which you are comparing your bedside method is sufficiently precise (ie, has high reproducibility and repeatability), and the expected level of change in the body composition compartment is sufficiently high to be detected by that method, then one can evaluate the ability of a bedside method to measure that change. The minimal detectable change (MDC) is an important concept to keep in mind, as it is defined as the minimum change that must occur in a body compartment to achieve statistical significance at the group mean level; it is determined by the precision of the method, and it is expressed as a percentage (so it can be related to the size of the compartment being measured). The %MDC can be calculated as follows 78 : When comparing a bedside method with a reference method for its ability to measure change, it is important to know the precision and MDC of the method. If a bedside method's MDC is 6% for FFM, a measured change in FFM <6% could be erroneous (ie, it may or may not reflect a real change in body composition because it is below the threshold for detection). MDC will be discussed with regard to individual methods in subsequent sections. Another consideration for measuring body composition changes over time is the safety and efficacy of conducting repeat measurements by a method. Whereas multiple dilution, DXA, and CT would not be advisable to repeat over short-term follow-up due to logistical (dilution) and safety (DXA and CT) reasons, bioimpedance and ultrasound measures can be repeated frequently without concern. A review of the aforementioned reference methods will be presented next, followed by discussion of bedside techniques.
Reference Methods for Lean Tissue Assessment in Clinical Research: Multiple Dilution, DXA, and CT

Multiple Dilution
In the context of this discussion, multiple dilution techniques are commonly used to produce reference values for BCM and the fluid compartments to validate bioimpedance techniques.
Multiple dilution typically involves the use of tritium ( 3 H), deuterium ( 2 H), or 18 O as a tracer for TBW determination, in combination with a tracer such as bromide for ECW determination. By subtraction, ICW can be calculated, and from ICW, an estimate of BCM can be determined. The use of 3 H is far less common, due to its radioactive nature, and 18 O is typically only used when given in combination with 2 H as doubly labeled water for total energy expenditure determination. In one approach, multiple dilution entails taking a predose blood or urine sample and then allowing a 3-to 5-hour equilibration period following dosing with deuterium oxide and sodium bromide solutions (with longer periods for individuals with expanded ECW, including those with extreme obesity, particularly for ECW determination by bromide dilution 79 ) before a final postdose blood or urine sample is collected. Deuterium enrichment of the biological sample may be determined by isotope ratio mass spectrometry [80] [81] [82] or Fourier transform infrared spectrometry, 83 and bromide enrichment can be determined by high-performance liquid chromatography 84, 85 or nondestructive liquid X-ray fluorescence. 86 The reader is referred to the International Atomic Energy Agency website resources 87 and the excellent chapter by Schoeller 88 on this topic. Deuterium dilution for the determination of TBW has a reported precision of 1%-2%. 78, 80, 81, 88, 89 The precision of ECW by bromide dilution is less well characterized but has been estimated to be attainable at 1%-3%. 78, 88 The determination of ICW by the multiple dilution technique has a somewhat lower precision, because it is derived by subtraction (TBW -ECW = ICW), and thus the errors in TBW and ECW lead to a propagation of error in the determination of ICW. Thus, it has been estimated that the ICW calculation by this approach has a relative precision of approximately 2.5%. 88 It should be noted, however, that most research studies report precision estimates that are typically derived from repeated analytical measures of the final tracer concentration in biological samples, rather than repeated measures of TBW or ECW within a particular subject. This is because of the time required for clearance of tracer concentrations from the body, which makes it difficult to conduct repeated measures over the short term (ie, days apart), although separation by 2 or more weeks in a physiologically stable person and/or the use of 2 different tracers for the same compartment used simultaneously provide other ways of estimating precision. 80, 81, 88, 89 When precision can be determined by using 2 different tracers or by taking multiple measures to get a total CV, the contribution of biological variation can be calculated by subtracting the analytic error CV (from repeat analyses of the same sample or multiple samples drawn at the same time point for a subject) from the total precision CV as 80 Total CV Analytical CV Physi al Error CV
It should be noted that Schoeller's group 80 applied this method to calculate the precision of total energy expenditure estimates using doubly labeled water; however, the concept can be applied to the determination of TBW by dilution methods as well. They reported a precision of 1.8% in TBW determined by 18 O and 2 H within the same subject; thus, it is certainly possible to achieve excellent precision with dilution techniques (and to define it by using 2 different tracers for the same compartment). 80 This raises another concern with dilution techniques, in that the use of different tracers (or the same tracer but applied using different protocols) can lead to differences in the dilution space that is used to estimate the fluid compartment; in addition, when a bedside method (eg, bioimpedance) developed using one tracer protocol is compared with a different one, large scaling differences may occur that could be interpreted as error in the bedside method when in fact it may be a systematic error in the reference. Schoeller et al 81 have reported a systematic error of 3% in the TBW measured by 18 O compared with 2 H. However, this is not likely to be a prominent concern in the validation literature; most studies of body composition will not use both tracers simultaneously (ie, doubly labeled water), unless they are also estimating total energy expenditure. These types of issues are not always easy to discern. If one is measuring fluid volume changes, at a minimum, it is important to keep in mind that the estimated %MDC 78 based on the aforementioned precision estimates would be ~3%-5% for TBW by deuterium dilution and ~3%-8.5% for ECW by bromide dilution of the total volume. Similarly, the %MDC for ICW by multiple dilution would be at ~7%. True precision estimates based on repeated measures are not typically done in most research studies using dilution, so the %MDC for these compartments could be higher. To minimize error when a multiple dilution approach is applied in a clinical research study, it is advisable to adhere closely to standardized protocols 88 and to obtain sample analyses of deuterium and bromide enrichment through collaboration and/or contract with established investigators and facilities. With that approach, multiple dilution can be a relatively affordable technique for the clinical researcher, compared with DXA or CT scanning; however, every effort should be made to minimize the risk of error as the study protocol is developed.
DXA
DXA scanners are becoming fairly commonplace in medical centers across the United States. DXA is commonly used as a reference method for the validation of bioimpedance and other bedside techniques to quantify FFM and LST. DXA is also used to generate a reference value for skeletal muscle mass; a value for appendicular skeletal muscle mass (ASM) is generated by summing the LST of the arms and legs. The ASM index can then be calculated by dividing the arm and leg LST by height squared. DXA-generated ASM and ASM index values have been used to define sarcopenia (see Table 1 ). 10, 90 Briefly, the DXA method requires an individual to lie down on a scanning table, and low-dose X-rays of 2 different energies pass through the body; a whole-body scan typically takes 10-20 minutes. An image is created as the photon detector measures the differential attenuation (or absorption) of the low and high X-ray energy by the soft tissue and bone. Soft tissue is further delineated into fat mass and LST, thus resulting in 3 body compartments: fat mass, LST, and bone mass (and density). Traditionally, weight and size limits constrained the use of DXA instruments in individuals with extreme obesity, but newer instruments allow for larger and heavier individuals to be scanned. DXA has a high degree of precision, with reports of 1%-2% CV for LST. 40, 91, 92 The MDC 78 for DXA-measured LTM based on these precision estimates would be 3%-6%.
CT
CT is another imaging technique that has been used to estimate lean tissue in the clinical research setting. It involves exposure to high-dose radiation and yields a highly accurate quantitative and qualitative image of skeletal muscle tissue, as well as total and regional adipose tissue, visceral organs, and bone from the detection of different X-ray attenuation. 29 Given the high-dose radiation exposure and the high cost, CT as a method for determining skeletal muscle is generally limited to those patients for whom a CT is ordered for diagnostic and other clinical reasons. Thus, one of the primary clinical populations in whom CT has been successfully used for lean tissue assessment and monitoring has been individuals with cancer. 93, 94 The precision of CT has been reported to be 1% or less for the evaluation of skeletal muscle, 95 which translates to an MDC of <3%. The reader is referred to the excellent tutorial by Prado and Heymsfield 29 in the November 2014 issue of the Journal of Parenteral and Enteral Nutrition for a more complete discussion of the advantages and limitations of DXA and CT as reference techniques.
Bedside Methods for Lean Tissue Assessment: Bioimpedance and Ultrasound
Bioimpedance
Bioimpedance is the bedside approach that has been most widely investigated in clinical research and used by clinicians for assessment purposes in Europe and elsewhere around the globe, in large part due to the affordability, portability, and ease of use of bioimpedance devices. 96 A bioimpedance measurement takes less than 15 minutes and is completely noninvasive, making it advantageous for repeat measurements. Like most body composition methods, bioimpedance devices do not directly measure body composition; they provide indirect estimates from the measurement of resistance of body tissues to an electric current. All bioimpedance techniques involve the application of a weak, alternating current at one or more frequencies, through leads attached to the body through current injection electrodes or through direct contact with electrodes in the case of stand-on scale devices. The differential flow of the current varies depending on the body composition; electrolyterich components, including blood and muscle, easily conduct the current, whereas fat and bone do not. The drop in voltage as the current passes through the body (ie, impedance) is detected through the voltage detection electrodes, and the impedance data (resistance, R; reactance, X; impedance, Z; and phase angle, PA) are recorded by the bioimpedance device. 97 Some devices may only measure Z; it should be noted that R and Z are not interchangeable in BIA equations. Furthermore, different devices have different electronic circuitry, and the raw data generated cannot be considered interchangeable, although interdevice differences have not been well explored in the literature. Although no difference was detected between R and X measured by the RJL (RJL Systems, Clinton Township, MI) SF-BIA and Xitron 4000B and Hydra 4200 (Xitron Technologies, San Diego, CA) BIS devices, 46 Chumlea et al 98 reported a difference of ~1%-1.5% in R values measured by the Valhalla (Valhalla Scientific, San Diego, CA) and RJL SF-BIA instruments that they corrected for in their FFM estimates from the National Health and Nutrition Examination Survey III (NHANES III) data. Although interdevice differences may not always be substantial, one should be wary of applying bioimpedance data from a particular device to an equation that was developed using a different device or a different approach (eg, whole body vs segmental).
The extrapolation from raw impedance data to volume or mass depends on several key assumptions, including that the body comprises 5 cylinders of uniform cross-sectional area, and height is an acceptable surrogate for the length of the conductor (ie, the distance between electrodes), among others. Body geometry assumptions are violated in individuals with obesity and in those with longer or shorter than average limbs. Basic concepts about bioimpedance are presented in an excellent online tutorial through the University of Vermont. 99 There are many different ways that bioimpedance can be applied to estimate whole-body lean tissue (FFM or BCM) or fluid volume (TBW, ECW, or ICW) estimates using data generated by SF-BIA or multifrequency BIA (MF-BIA) or bioimpedance spectroscopy (BIS) devices. The reader is referred to several recent reviews that describe the different ways that bioimpedance may be used and the differences in technological applications and underlying assumptions between the 3 primary categories of bioimpedance techniques, 96 ,97,100-104 as well as currently available devices on the market, which range in cost from ~$500 to $20,000. 97 In general, the level of precision (ie, repeatability) produced by SF-BIA and MF-BIA devices is typically very good, with 1%-2% variability between repeat measures being reported in the literature. 92, 101, 105 BIS devices may be somewhat more variable, due to the technical difficulties in producing stable measurements at the extremes of frequencies, but even most BIS devices have been reported to produce fairly precise measurements (2%-3%). 46, 106 Based on these precision estimates, the sensitivity of BIA/BIS techniques to measure whole-body composition changes can be calculated; for example, the MDC in FFM by SF-and MF-BIA has been estimated from 3%-6% 78 and in TBW by BIS was observed to be 5%-8%. 106 On the other hand, the level of accuracy in whole-body measures produced by various bioimpedance techniques, particularly in clinical populations with fluid overload, has been observed to be somewhat more variable.
Precision and accuracy of bioimpedance techniques are influenced by a number of factors, including patient (eg, degree of adiposity, fluid and electrolyte status, skin temperature) and environmental factors (ambient temperature, proximity to metal surfaces and electronic devices), the assumptions underlying prediction (SF-BIA or MF-BIA) or modeling (BIS) equations, instrumentation factors, and variations in measurement protocol. Close adherence to recommended measurement protocols for body weight 107 (see Figure 3 ), height 107 (see Figures 4 and 5) , and the bioimpedance 96,108,109 measurement itself (see Table 2 ) is important to optimize the results of bioimpedance measurements and to minimize potential errors.
For example, how electrodes are placed is quite important. Depending on the device and whether the aim is to obtain whole-body or segmental measurements, adhesive electrodes may be placed in a standard wrist-ankle tetrapolar arrangement on the hand and the foot of one side of the body, on both sides of the body on both limbs using an 8-electrode arrangement, or on different segments of the body. 97, 110, 111 Stand-on devices do not involve use of adhesive electrodes but rather direct contact with the electrodes at the feet and/or hands, depending on the device. Different devices and electrode placement techniques (eg, for whole-body and various segmental measurements) should not be considered interchangeable. For example, raw data obtained by a stand-on device should not be applied to an equation developed from data derived using a wrist-ankle tetrapolar electrode approach and vice versa, as to do so would introduce error into the estimate. The most important consideration is the consistent placement of the voltage detection (proximal) electrodes at standardized anatomical sites; for example, for wrist-ankle tetrapolar placement, the proximal electrodes are placed at specific sites on the dorsal surface of the wrist (eg, between the styloid processes of the ulna and 
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• Test the accuracy of your measuring scale by using standardized weights. It should have accuracy to 0.1 kg.
•
If it is a portable scale, ensure that it is on a level surface and horizontal, using a portable spirit level.
Ensure that the individual being weighed has voided the bladder prior to measurement, and that all external clothing (e.g. coats, sweaters, hat, shoes etc.), heavy jewelry, watches, and pocket contents have been removed.
Ensure that the scale reads '0' prior to asking the individual to step on it.
• Ensure that the individual being weighed is standing on the center of the scale platform without touching anything or anyone.
• Take two sequential measurements. Ask the individual being weighed to step off the scale and re-zero it in between each measurement.
• If the readings are not ±0.1 kg of each other, repeat the process until you have two measurements that are, and then record the mean of the two. 
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• Test the accuracy of your stadiometer using a standardized pole of known height.
• Ensure that the stadiometer is vertical, using a portable spirit level.
• Ensure that the individual being measured has removed shoes, hats, and heavy external clothing prior to measurement.
• Ask that the individual remove any hair clips or headbands, and undo braids from the top of the head.
• Ask that the individual back up to the stadiometer facing out, with the heels touching the base.
• Ensure that the individual's spine at the level of the pelvis and at the shoulder is just touching the stadiometer, but that the individual is not leaning on the stadiometer.
• Check the position of the head. In an adult, position the head in the Frankfort plane (see Figure 5 ).
• Ask the individual to take a deep breath and stand tall just prior to the measurement and hold until the measurement is complete.
• Gently lower the head plate down onto the crown of the individual's head, pressing down the hair, and read the measurement at eye level.
• Repeat the measurement process two times. If the two measurements are not within 2 mm of each other, repeat the process until you achieve two consistent measurements. Record the mean of the 2 measurements. radius, ie, midline between the wrist bones) and anterior surface of the ankle (eg, between the medial malleolus formed by the lower end of the tibia and the lateral malleolus formed by the lower end of the fibula, ie, between the bony protuberances on the inner and outer sides of the ankle). Although it is common to have the electrode dissect the anatomical mark midline, different device manufacturers may suggest slight variations (eg, leading edge, midline, or trailing edge at the anatomical mark). Small variations in the placement of proximal electrodes can introduce error to impedance measurements (by ~2%). 109 When applying data to an equation or making comparisons to reference data, one should follow the same procedure for electrode placement to optimize accuracy. 109 Although it is often recommended that electrodes be placed at least 5 cm apart in adults, this may not always be possible; it has been suggested to move the distal electrode to create sufficient separation or to allow a 3-cm separation in children. 96 The most important point is to keep the proximal electrodes at the anatomical marks and standardize the distance for follow-up measurements 106 ; fixed-distance (5-cm) electrodes have been shown to improve reproducibility in follow-up measurements, particularly in men. 106 The placement of electrodes for segmental measurements to obtain consistency in the anatomical location and distance between them is also important to minimize potential error, particularly for longitudinal measurements, and to optimize accuracy when applying data to previously established equations and comparing data with reference data generated from those equations. 102 Protocol deviations (eg, failure to abduct the limbs) can contribute substantially to the error in measurements (eg, can affect 
Electrodes and leads
Use electrodes with sufficient surface area (≥4 cm 2 ); store electrodes in sealed bag away from heat; use device-specific leads provided by manufacturer. Electrode placement Place electrodes at least 5 cm apart, if possible; proximal electrodes should never be moved from standard anatomical site placement; if necessary, the distal electrodes may be moved to achieve at least 3 cm of separation; the most important thing is to measure and record distance between electrodes to ensure placement consistency for follow-up measurements. 
Timing of measurement
If individual is ambulatory, individual should assume a supine position for ~5-10 minutes; standardize the timing for measurements by noting the time when the individual assumes the supine position and the time when you take the measurement (eg, at 10 minutes), and ensure consistency of timing for all followup measurements. Note if individual is confined to bed. Repeat measurements Repeat measures recommended for research studies.
resistance measurements by 2%-3% for minor deviations 109 and 18% and 43% for skin-to-skin contact with crossed legs and contact of hands to the waist, respectively 108 ). Body positioning is also quite important; after a person assumes a supine position, there is an immediate increase in impedance that occurs within the first 10 minutes and then a more progressive increase in impedance over the next several hours, reflecting the movement in fluid distribution toward the trunk. 108 The greatest increase in impedance occurs at lower frequencies, reflecting the decrease in ECW. BIS-measured ECW decreased by approximately 3% and ICW increased by just less than 5% after moving from a semi-upright to a supine position for 30 minutes. 112 Those who resume an upright position for 5 minutes return to presupine measurements. 112 Because most bioimpedance reference data are measured within 5-10 minutes after patients assume the supine position, it is not recommended to apply such reference data to whole-body measurements taken from individuals who are restricted to bed rest, as errors in TBW and, in particular, ECW will be observed. 108 Similarly, many investigators take measurements on the right side of the body, which may or may not be the dominant side; thus, much of the available reference data have been generated from right-sided measurements. It is estimated that impedance measurements can vary by approximately 2% between the dominant and nondominant side of the body 109 ; thus, it is recommended to follow the same protocol that was used to generate the equation and/or reference data that you intend to use and to maintain consistency in the side of body for longitudinal measurements. 96 Increasing skin temperature by 6.5°C (11.7°F) also has a significant inverse effect on impedance, increasing 50-kHz estimates of TBW by approximately 13%; it is recommended that ambient temperature be maintained between 22.3 and 27.7°C (72.1-81.9°F) to minimize these effects. 109, 113 Other deviations (eg, failure to clean skin with alcohol or failure to remove metallic objects from the body prior to measurement) are associated with smaller errors (<1% effect on resistance). 109 The reader is referred to several excellent sources that describe errors associated with protocol violations. 106, 108, 109, 113 In general, the application of all varieties of bioimpedance techniques for the estimation of whole-body compartments has been accepted as reasonably accurate for the assessment of healthy nonobese individuals and for large-scale epidemiologic studies (ie, mean-level accuracy), but they have typically been questioned in terms of their applicability to the clinical setting due to variability at the individual level. That variability has been attributed to random and/or systematic errors that are sufficiently problematic to raise doubts about the capacity of bioimpedance methods to accurately quantify and monitor changes in whole-body volumes and masses, and the question has been raised if bioimpedance techniques can offer any advantages beyond simple anthropometrics to the assessment of nutrition status. 114 On the other hand, bioimpedance data are typically highly correlated with lean tissue and fluid volumes measured by reference techniques, as well as with other indices of nutrition status, and so the primary problem seems to be the degree of variability in individual measures when comparing reference and bioimpedance methods. It has been proposed that the failure to account for precision error in the reference techniques (particularly multiple dilution) used to validate bioimpedance methods may have contributed (at least to some degree) to erroneous conclusions about the capacity of bioimpedance techniques to estimate body composition. 75, 115 Indeed, one recent study reported that bioimpedance techniques had errors of a similar magnitude to those observed in the reference (dilution) techniques and underscored the importance of reference method precision when interpreting validation data. 115 Although bioimpedance techniques have been criticized for their limitations, particularly when applied to individuals with acute and chronic disease as well as individuals with obesity due to the potential violation of underlying assumptions, 97 bioimpedance remains one of the few inexpensive, noninvasive, and portable bedside options currently available to clinicians.
It is not unreasonable to suggest that bioimpedance techniques might be able to contribute important objective information that may help the clinician to identify sarcopenia and malnutrition, whether or not a truly accurate measure of lean tissue or a fluid compartment volume can be obtained. Where bioimpedance techniques (particularly MF-BIA and BIS) may play an important role is in those individuals who have muscle loss that is not evident upon visual examination (including individuals with sarcopenic obesity) and those with excess ECW. Furthermore, bioimpedance techniques may be useful in monitoring the early changes in lean tissue that can happen with inflammation associated with chronic disease conditions (eg, cancer and HIV infection). 116, 117 An objective method for monitoring anabolic changes in response to nutrition and other interventions would also be highly advantageous to the clinician. Of note, bioimpedance is being used in dialysis centers around the world, based on a growing body of literature demonstrating that bioimpedance techniques (segmental MF-BIA and, to an even larger extent, wrist-ankle BIS) can be used to monitor fluid status and assess dry weight in individuals on dialysis. [118] [119] [120] [121] [122] [123] [124] Finally, although much focus has been paid to evaluating the accuracy of bioimpedance techniques to quantify lean tissue and/or fluid volumes in absolute terms with variable success, it has been suggested by many that its true benefit may be in different applications (eg, by getting away from whole-body volume or mass estimates and using the data as markers to reflect lean tissue changes, nutrition status, and/ or clinical outcomes). 125, 126 These and other novel applications of bioimpedance techniques are described in several recent reviews 97, 100, 127 and are an active area of research. It is important to understand how the different bioimpedance approaches (ie, SF-BIA, MF-BIA, and BIS) use the bioimpedance data to generate whole-body lean tissue mass (eg, FFM, LBM, or BCM) or fluid volumes (eg, TBW, ECW, or ICW), because they vary in terms of underlying assumptions and thus their theoretical applicability to different clinical conditions. For example, applying an SF-BIA equation to estimate ICW in an edematous patient is likely to produce substantial error because of the limitations of using just one frequency, whereas an MF-BIA or BIS device would offer at least the theoretical potential of differentiating ICW from ECW by measuring impedance at low frequencies. Furthermore, assumptions regarding normal body geometry and consistent, predictable hydration of FFM, as well as fluid distribution between the intra-and extracellular compartments, are frequently violated in the setting of acute and chronic illness. The generation of whole-body lean tissue estimates by SF-and MF-BIA requires the utilization of empirically derived prediction formulas that are often erroneous when applied to populations that differ fundamentally from those in which the formula was developed. The reader is referred to several recent reviews on bioimpedance 97, 100, 102, 103, 128 for more complete descriptions of each of the major bioimpedance approaches and for summaries of the validation literature. 33, 96, [129] [130] [131] A basic description of each of the major approaches to the use of bioimpedance, including novel applications of the raw data, will be presented next.
SF-BIA. SF-BIA devices measure impedance variables (ie, R, X, Z, and PA) at a single frequency, typically 50 kHz. To obtain an estimate of a body compartment, it is necessary to apply one or more of the impedance variables (most commonly Ht 2 /R, which relates the length of the conductor [ie, height of the body] to volume [eg, TBW]) to a prediction equation. Because components of the body (eg, TBW, ICW, FFM, BCM, and LST) are all intercorrelated, impedance can be used to predict any body composition compartment, if calibrated sufficiently to a reference method. 132 Many prediction equations have been published in the literature, almost as many as there are studies that have been conducted to evaluate this approach. SF-BIA equations are typically developed by regressing impedance data against a reference method for some body composition variable (eg, FFM), perhaps using DXA or a 4-compartment model as the reference, in a homogeneous population sample. Ideally, the population-specific equation that gets developed is subsequently cross-validated in a separate sample (and if not cross-validated, the equation should not be used). It is important to realize that the measurement of impedance at only one frequency (ie, 50 kHz) is theoretically unable to differentiate between ECW and ICW (or BCM); in fact, in the clinical setting, it is not likely to be sufficiently high to quantify the entire TBW. This will become more clear once we have discussed BIS. Indeed, many SF-BIA devices produce elaborate output consisting of ECW, ICW, BCM, FFM, and more; however, they are simply predicting these compartments based on assumptions of static relationships between the body compartments from normative data; these assumptions may hold sufficiently true in healthy individuals. SEE for predictions of FFM by various SF-BIA equations have been observed to range from 1.8-4 kg in healthy normal-weight adults and from 1.6-3.4 kg in in healthy elderly individuals and as high as 8.8 kg in overweight women, compared with DXA, 4-compartment models, and/or densitometry. 104 Although they reported %body fat (%BF), rather than FFM, it is interesting to note that in women with extreme obesity (mean %BF 51.4% ± 3.6%), Das et al 27 observed limits of agreement of ±5.1% and ±5.8% for 2 SF-BIA equations, as well as ±2.2% for 2 H dilution for %BF measures, compared with %BF by the reference 3-compartment model. After gastric bypass-induced weight loss (and -16.8 ± 8.5 %BF), the methods agreement worsened considerably, with limits of agreement for the measures of change in %BF compared with a reference of ±8.5% (estimated PE calculated as per Ward 75 of 51%) and ±9.6% (estimated PE 57%) for 2 SF-BIA approaches, compared with ±5.7% (estimated PE of 33.9%) for 2 H dilution, underscoring the particular difficulties (by any method) when measuring changes in individuals with extreme obesity undergoing massive weight loss. In clinical populations, similar or higher errors have typically been observed for FFM and SM estimates. 133, 134 For a clinician who wants to evaluate lean tissue using an SF-BIA device, he or she is faced with the dilemma of choosing a prediction equation (from the abundant literature on the topic) that ideally matches the patient that he or she wishes to assess. The difficulties of making such a selection cannot be overemphasized. This is one of several limitations to the application of SF-BIA in the clinical setting, regardless of questions about potential accuracy for whole-body lean tissue estimates.
It has been suggested by a growing number of researchers that a potentially more useful approach to the use of SF-BIA might be to apply the raw data to a published equation that has established normative reference values 12, 13, [135] [136] [137] or to generate the PA and compare that with published normative reference values. 138, 139 Although many BIA equations have been published, several different applications of 50-kHz data for estimating lean tissue have been primarily advocated, based on the concept of normalizing lean tissue data to height to create a standardized measure that might be used to indicate nutrition status. 140 One is to apply the 50-kHz data to a validated multiethnic prediction equation for skeletal muscle mass (SM) and then to calculate the skeletal muscle index (SMI) 12 ; this has been incorporated into the definition of sarcopenia (relabeled as "whole-body fat-free mass index without bone" by Fearon et al 14 ) as part of the international consensus definition of cachexia, 14 based on evidence that it correlated well with MRI 137 and predicted functional status in older adults. 12 137 Individual-level agreement was not evaluated, and thus, it is not known how well this equation can predict SMI for bedside assessment. The first version of the SMI using this equation was calculated by dividing the skeletal muscle mass by body weight in kilograms and multiplying by 100.
12 Subsequently, these investigators calculated SMI by dividing the skeletal muscle mass by height in meters squared and identified cutpoints to define sarcopenia based on physical disability 13 ; these cutpoints have been published as potential defining cutpoints (among others from the literature) in the European consensus paper on the definition of sarcopenia. 17 Reference values for sarcopenia cutpoints based on the above BIA-derived SMI estimates are presented in Table 1 .
Another proposed way to apply 50-kHz data is to calculate FFM using a validated SF-BIA equation developed from healthy reference population data. 98 135 Note that the authors did not calculate PE, but it was estimated from their data based on the calculation of 2 CV for the reported difference between methods, which would be 1.7 SD × 2/mean FFM of 54 = 6.3% error.
Chumlea et al 98 also developed and cross-validated FFM SF-BIA prediction equations for men and women (ethnicity combined) based on the NHANES III data; however, FFMI values were not calculated in their study, and only the mean and SD for SF-BIA-predicted FFM in various age groups were presented rather than percentile data. 141 Means and SD for FFM are inherently limited and should be interpreted with caution. It would be advantageous to have reference data by percentiles for FFM (and FFMI) from the NHANES III equations, if they are to be useful as a way to identify individuals with low muscle mass or at increased nutrition risk. Schutz et al 136 have proposed that FFMI values below the fifth percentile cutpoint from healthy reference norms could be interpreted to suggest compromised nutrition status, although this is not well established, and fifth percentile cutpoints for FFMI are only available based on Swiss white population data, and thus, their application to other ethnicities and population samples may be limited. Nevertheless, the fifth percentile reference cutpoints defining low FFMI calculated by the Geneva equation, 135, 136 based on a Swiss white population sample, range from <12.9 and <16.6 kg/m 2 for women and men, respectively, older than 75 years, to <14.4 and <17.2 kg/m 2 for women and men, respectively, 35-54 years in age.
Some studies reported that a low FFMI in individuals (calculated by the Geneva equation 135 but defined by slightly higher cutpoints 142 than previously reported 136 ) was significantly associated with increased length of stay compared with those with normal or better values. 6 Another recent study 143 in a Brazilian population sample reported that low FFMI (defined by the Geneva equation 135 and Kyle cutpoints 136 ) was correlated with malnutrition diagnosed by subjective global assessment. Low FFMI (defined by the Kyle cutpoints 136 ) but with FFM estimated by a BIS device with the device software (i.e., not by the Geneva equation) before surgery was shown to be independently associated with a higher prevalence of postoperative infections and increased length of stay in a Dutch ICU study sample. 144 Another group recently reported 145 that discrepancies between 2 different bioimpedance devices (an SF-BIA device and a BIS device) were evident for FFMI values that resulted in significant differences in the number of individuals identified at nutrition risk; however, it should be clarified that the authors did not simply use the raw bioimpedance data generated by the 2 devices to calculate the Geneva equation FFMI (which would be a more appropriate way to make that comparison). Rather, they took the FFM values generated by the proprietary software in the SF-BIA device and the FFM value generated by the modeling and mixture-based equations programmed into the BIS device. This important detail was overlooked in a recent review by this author. 97 Thus, it is not clear that important differences in actual impedance values were evident in that study. Furthermore, it should be emphasized that it is not recommended to use the cutpoints generated by one method (ie, using the Geneva SF-BIA FFM equation) to interpret a measurement made by a completely different method (ie, FFM generated by device software). The only way that it could be advocated to use the Kyle reference cutpoints 136 for FFMI would be to use the raw bioimpedance data to calculate FFM by the Geneva equation 135 and then convert to FFMI. That said, significant differences between devices might yield different values for the raw bioimpedance data that would affect the end FFMI or SMI values, as has been observed with reference data for PA, which will be discussed next. PA is a simple bioimpedance parameter generated from the arctangent of the ratio of reactance to resistance at 50 kHz (see Figure 6 ). It can be calculated from the following equation 126 :
Although it has been purported to relate to cell biologynamely, membrane integrity, permeability, size, hydration, and capacitance-it is not entirely clear that there is a physiologic foundation for the observed statistical associations. Nevertheless, a low PA has been reported to be an independent prognostic indicator of disease and/or nutrition risk/poor nutrition status in a variety of clinical populations, including HIV infection, 146, 147 cancer, 148-151 chronic heart failure, 152 cirrhosis, 153 stage 5 chronic kidney disease, 154 and hospitalized elderly. 155 Normative values for PA measured at 50 kHz have been published based on healthy German, 138, 156 Swiss, 157 and American 139 populations; however, fifth percentile cutpoints are available only from German 138 and American 139 reference data. These fifth percentile cutpoints are presented in Table 3 . The mean reference data 138, 139, 156, 157 (see Table 4 ) can be used to calculate the standardized PA (SPA), which involves creating a z score by using the following equation 139 :
SPA
Observed PA Mean PA SD where the mean and SD are
from reference values.
The SPA was reported to be a significant independent predictor of malnutrition and decreased functional status, as well as 6-month survival. 158 A standardized PA below -1.65 has been suggested as a cutoff to indicate malnutrition in individuals with cancer, representing the 5th percentile. 159 Age, sex, and BMI are major factors that may affect the PA; Bosy-Westphal et al 138 have published age-, sex-, and BMI-specific reference cutpoints. Others 139, 156, 157 have presented age-and sex-specific reference data without delineating BMI categories. Observed differences between published reference cutpoints may be attributed to device-, BMI-, and/or population-specific differences. These issues are addressed quite well in the recent review by Norman et al 127 ; in addition to discussing the clinical use of 50-kHz PA and SPA, they also discuss the applications of 50-kHz bioelectrical impedance vector analysis (BIVA) originally developed by Piccoli et al 160 for the assessment of hydration status. Whether or not PA or SPA can be used to identify individuals with muscle loss (compared with reference methods) or to uniquely contribute to the diagnosis of malnutrition beyond other diagnostic criteria has yet to be established.
MF-BIA.
MF-BIA approaches may be taken using data collected by an MF-BIA device or by a BIS device, although the data are handled quite differently by the BIS technique, as will be discussed later. MF-BIA is quite similar to SF-BIA, but instead of just one frequency, MF-BIA devices measure impedance at 2 or more frequencies, typically at 4 or 5 frequencies, including at least 1 low (most commonly 5 kHz) and several higher ones (typically 50, 100, 200, and 500 kHz). As with SF-BIA, the MF-BIA approach to estimate whole-body volumes or lean tissue masses typically involves the use of linear regression-derived, population-specific equations. However, it has the advantage of taking measurements at a very low frequency and one or more high frequencies and thus theoretically allows for the estimation of both ECW and ICW. Separate equations are typically developed to predict ECW and TBW based on reference values derived from bromide dilution and deuterium (or tritium) dilution, respectively, in a particular sample population. Subsequently, ICW can be estimated through subtraction (ie, TBW -ECW = ICW). Alternatively, total body potassium reference values may be used to develop prediction equations for ICW and BCM. DXA, 4-compartment models, densitometry, or deuterium dilution data may be used to develop prediction equations for FFM or other lean compartments. Another less conventional approach to the use of MF-BIA data, if measurements are taken at 3 or more (and ideally 6 or 7) frequencies, is to model the data through nonlinear least squares curve-fitting techniques similar to those applied in BIS, 161 although this approach has not been well studied and is likely to be less robust than the BIS approach of using spectral data measured at 50 or more frequencies, which will be discussed later.
Despite the added advantage of measuring at multiple frequencies, the more typical MF-BIA prediction equation approach is limited for whole-body estimates by the same complaints that may be made about the SF-BIA prediction equation approach, particularly in the clinical setting and in individuals with obesity, 49 where underlying assumptions may be violated. Far fewer MF-BIA equations than SF-BIA equations have been published in the literature, but some have been specifically developed for lean tissue and/or fluid volumes (TBW, ECW, and/or ICW) in healthy individuals, [162] [163] [164] [165] [166] [167] and some have been developed for clinical assessment of fluid volumes (eg, in surgical patients 168, 169 and individuals with HIV infection 146 ). Although MF-BIA equations may do reasonably well in healthy individuals, reports of errors are quite variable in clinical populations, with reported SEE of 2.0 for ECW and 4.0 for TBW in surgical patients, 168 limits of agreement of ±9 and ±14 L for TBW and ECW measures in individuals with cirrhosis, 170 and limits of agreement of ±18% for ICW estimates in individuals with HIV infection. 146 Although clinicians may search the literature and identify appropriate equations with which to apply MF-BIA impedance data to estimate whole-body volumes or masses in their particular patient, more often than not, time will be limited, and the only alternative will be to accept the output generated by the device, the underlying equations for which may not be readily available, being considered "proprietary" by the manufacturer. The raw data generated by an MF-BIA device could have utility independent of whole-body volumes/masses by allowing a clinician to evaluate the 50-kHz PA as well as a high to low frequency (eg, 200/5-kHz) impedance ratio, as will be discussed next. Unfortunately, some MF-BIA devices do not provide the raw bioimpedance data but rather just produce whole-body volumes or masses with no indication to the clinician which equations and/or specific variables were used to generate them. Any bioimpedance device that does not provide the raw data and/or uses "black box" proprietary equations is not as useful as it could be. These issues are major barriers facing the further development of bioimpedance for clinical use.
Given the concerns about the accuracy of whole-body measures in the clinic setting, there has been significant interest in the utilization of a simple ratio of impedance measured at 200 kHz to impedance measured at 5 kHz. Although it is possible to create ratios from impedance measured at other frequencies, the 200/5-kHz impedance ratio has been the most commonly investigated as a potential marker for nutrition status and/or disease severity, with worse outcomes the closer to 1.0 the ratio is. For example, higher 200/5-kHz impedance ratios have been observed in individuals with poor nutrition status, 171, 172 postoperative edema, 173 and impaired renal and cardiac function. 174, 175 Values >1.0 suggest device error.
In a study that included 151 healthy volunteers, normal values for this impedance ratio were ≤0.78 in men and ≤0.82 in women. 171 Values above these cutpoints were associated with more than a 4-fold higher risk of malnutrition, identified by low total body protein measured by neutron activation analysis. 171 Importantly, a high impedance ratio was reported to have a sensitivity of 79% and a specificity of 53% for identifying malnutrition. 171 Similar to the concept of using PA as a predictive variable, the simplicity of using a ratio to evaluate nutrition status has appeal, given that it requires no population-specific regression equations and gets away from the potential errors associated with wholebody estimates; however, for it to be clinically useful, reference cutpoints need to be established. Furthermore, just as is true with the PA, the use of the impedance ratio as a marker relies on a statistical relationship, such that other variables that are equally good at predicting nutrition status could be easier to measure. The question remains to be answered regarding whether the measurement of the 200/5-kHz or any other high-to low-frequency impedance ratio can improve upon the diagnosis of malnutrition beyond physical examination and other clinical data.
BIS. In contrast to SF-BIA and MF-BIA approaches, which require the use of a regression-derived equation to predict whole-body volumes or masses from raw data assuming a linear relationship, BIS devices use a more scientific approach based on biophysical modeling. 102, 176 Impedance spectroscopy is a well-known analytical technique used in materials and biological research; technological advances in the early 1990s facilitated the application of BIS for the assessment of in vivo body composition for the first time. 102 In contrast to SF-BIA and MF-BIA devices, BIS devices apply the electrical current (typically ≤800 µA) over a range of frequencies, from very low (eg, 1 or 5 kHz) to very high (eg, 1000-1200 kHz), measuring impedance data (ie, R, X, Z, and PA) at 50 or more frequencies. The application of a variable-frequency current to biological tissue yields a response that gives rise to a semicircular graphical relationship between R and X due to the cell membrane capacitance (C m ); this relationship is best represented by the standard and classic Cole model of biological tissue. 177 Nonlinear least squares curve-fitting techniques are applied to the spectral data, generating a semicircular Cole plot and Cole model terms R E , R I , C m , and exponent α (see Figure 6) . These terms can then be used to provide estimates of ECW and ICW through algorithms that will be discussed later.
Theoretically, at an exact very low frequency, the ECW is measured independent of ICW, and at an exact very high frequency, the ICW is fully measured. However, it is not possible to measure at frequencies >10 MHz or <1 kHz, and thus, using nonlinear least squares curve fitting, data are fit to the 157,b Males (n = 2735) 7.3 ± 0.8 7.5 ± 0.8 7.2 ± 0.9 7.2 ± 0.9 6.6 ± 0.9 6.1 ± 0.9 5.3 ± 0.9 4.6 ± 0. 6.6 ± 0.8 6.6 ± 0.9 6.7 ± 0.8 6.5 ± 0.9 6.0 ± 0. can be derived; the exponent α term that is also a Cole model parameter has been discussed elsewhere. 176 To best solve for the primary components of the Cole model, sufficient data points are required; thus, impedance data are typically measured at 50 frequencies.
The characteristic frequency (f c ) is also computed from R E , R I , and C m ; it is defined as the point of maximal reactance or the frequency where the measurement is halfway between zero and infinity. 102 As you can see from Figure 6 , it is graphically represented as the top of the semicircular Cole plot. Theoretically speaking, at any frequency other than zero and infinity, the proportion of ICW measured varies with increasing frequency and when the tissue changes, causing a change in f c . 102 The BIS modeling approach is the only bioimpedance approach that actually calculates the f c . Although f c may in time have its own important clinical applications, for this discussion, it is useful to understand f c because it underscores an important advantage of the BIS modeling approach. 102 For example, at 10 kHz, there is more ICW measured than at 5 kHz, and at 50 kHz, there is less ICW measured if f c is 100 kHz than when f c is 30 kHz. Although 50 kHz is used to predict TBW, it is typically >20:1 away from where ICW is fully measured (ie, at infinitely high frequency). One of the assumptions made by SF-BIA is that 50 kHz is sufficiently high to predict TBW, but that is likely to only hold true in healthy people (for whom the fc is typically around 40 kHz and underlying relationships between compartments are not altered). 102 That will almost certainly not hold true in many individuals with acute and chronic disease, who may have significantly greater f c (eg, >200 kHz in individuals on dialysis 176 ). For these individuals, much higher frequencies would likely be needed. For more in-depth insight into this topic, the reader is referred to the excellent review by Matthie. 102 Interestingly, it has been suggested that the reason 50 kHz PA has been shown to predict nutrition status is because, for most individuals, 50 kHz exceeds their f c 102 ; it is quite possible that the application of PA as a marker of malnutrition might be improved by using the PA measured at the f c measured by a BIS device, but this remains to be investigated. Nevertheless, it is important to realize that no single frequency (5, 50, f c , 100, 200, 500, or even infinite kHz) is a measure of TBW but rather a mixture of ICW and ECW, which have substantially different (ie, 5:1) resistivities. 176 The only way to accurately estimate ECW and ICW is to independently evaluate them, and BIS is theoretically ideal to do this.
Typically, BIS devices are programmed with software that first models the data, using nonlinear least squares curve fitting and assuming that the fit is sufficiently good, then applies parameters (R E , R I , C m ) generated by the modeling procedure to calculate fluid volumes and other body composition compartments using a particular algorithm. The Cole model parameters can be applied to equations that were originally developed based on Hanai's mixture theory, 178 which, as it applies to humans, assumes that the electrical properties of tissues are affected by the mixture of conducting (eg, body water, electrolytes, muscle and other lean tissue) and nonconducting (eg, bone, fat) body components. The BIS approach involves several other key assumptions, including constants for estimating the specific resistivity of the ICW and ECW compartments (termed apparent resistivities or resistivity coefficients) and constants for body density and shape; these are likely sources of error in individuals with obesity and edema, who may vary from normal-weight shape and density. ICW and ECW resistivity coefficients used in device software algorithms may differ, depending on the manufacturer's decision to use published values or to generate its own from reference (eg, multiple dilution) data. Most commonly applied are the coefficients published by De Lorenzo et al, 176 which were derived from TBW and ECW determined by deuterium and bromide dilution, respectively, and by the Xitron 4000B (Xitron Technologies) BIS device in healthy normal-weight individuals, but coefficients have been generated in other populations, including individuals with extreme obesity. 47 The use of different dilution techniques and different BIS devices will yield different constants; this is a potential source of error in BIS measurements, although it has not been well studied. The original mixture theory-based equations for determining fluid volumes from BIS spectral data were first developed by Xitron Technologies in the early 1990s. Improvements were made after recognizing how the resistive properties of the ICW compartment were affected by adiposity, and those second-generation equations were published. 176, 179 Much of the published literature on BIS has evaluated the original Xitron-Hanai-based mixure equation approach using resistivity coefficients generated by the device manufacturer or those published by De Lorenzo et al 176 to estimate fluid volumes and/or FFM or BCM in various populations. In general, a similar pattern of errors in whole-body estimates has been observed with BIS as with other bioimpedance approaches-namely, good mean-level agreement but sometimes large variability at the individual level. For example, focusing on ICW given its relevance to lean tissue, relatively acceptable mean-level errors (SEE of ~1.5-2.5 L in ICW, approximately 8%-14% error) have been observed in healthy individuals. 180 BIS using the XitronHanai-based mixture equation approach was also shown in individuals with HIV infection undergoing treatment with oxandrolone to produce similar SEE estimates for ICW in absolute terms before (SEE 9%) and after (SEE 6%) treatment and to track changes in ICW (BCM) better than an HIV-specific SF-BIA equation, 116 but variability in individual measurements was in some cases quite large. 46 Wide limits of agreement (±5 L, compared with the mean change of ~4.4 L) were observed in measures of ECW changes in ICU patients with major trauma and sepsis. 181 Substantially greater error (with fixed and proportional bias, as well as wide limits of agreement) was observed for all fluid volume measures in individuals with extreme obesity. [47] [48] [49] Since then, it was determined that a significant portion of the error observed in BIS measurements came from the impact that adiposity had on the ICW estimates, and new equations that incorporated a correction for BMI were advocated and tested. 182 These revised equations, with the correction for BMI, are as follows The BMI correction reduced, but did not eliminate, the individual errors associated with BIS ICW measurements in individuals on dialysis and in healthy individuals, particularly in those at the extremes of BMI.
182
This same group has incorporated a new conceptual model (which will be referred to henceforth as the Chamney model) regarding the hydration of adipose and lean tissue based on cadaver data 183 into the BIS approach and is applying the technology to the problem of fluid management in individuals on dialysis. 184 In the most recently published version of the model, it is conceptually possible to quantify excess fluid and thus more accurately assess the lean tissue compartment, which they term "normally hydrated lean tissue." The ECW and ICW volumes calculated from the BMI-corrected mixture based equations could be applied to the Chamney model equations 183 :
. The validation of this approach to quantify lean tissue is limited by the fact that there is no clear reference method for specifically measuring the "normally hydrated lean tissue" compartment. However, it does appear that their approach, or some derivation, is being successfully applied to evaluate dry weight and the adequacy of dialysis in individuals with renal failure. 183, 184 It may be surmised that the better their modelderived estimates of excess fluid become, the more refined will be the estimates of lean tissue. The refinement of the apparent resistivity constants, among other factors, will almost certainly be a necessary part of that process. A recent report provides compelling evidence of the efficacy of this approach for lean tissue assessment. 185 Marcelli et al 185 reported that individuals on hemodialysis who had NH_LT values below the 10th percentile from healthy reference data had significantly higher mortality than those with higher values, suggesting that it could be indicative of malnutrition and poor clinical status. This is an exciting and promising area of bioimpedance application, and additional research is warranted to see if BIS-measured "normally hydrated lean tissue" can be used to evaluate muscle loss for diagnosing malnutrition and to track changes in response to nutrition interventions.
Ultrasound Measurements of the Quadriceps Muscle
Ultrasonography is a readily available, portable technique used for diagnostic and monitoring purposes in clinical settings. Good-quality ultrasound devices may cost $30,000-$50,000, making them slightly more expensive than the top-end BIS devices but far less expensive than a DXA or CT scanner. The application of ultrasound to measuring body composition is not entirely new; it has historically been used for assessing the abdominal adipose compartment to distinguish visceral and subcutaneous fat depots. 186 Much of the research that has been done on ultrasound applications in muscle tissue has come from the sport injury and neuromuscular disease fields. 187, 188 More recently, there has been growing interest in the use of ultrasound to quantify lean tissue at the bedside, particularly in the intensive care setting. [189] [190] [191] [192] For example, one recent study tracked loss of muscle mass in critically ill patients using ultrasound measures of the quadriceps muscle thickness.
192 Muscle thickness can be measured at one or more anatomical sites, and these values may be extrapolated to whole-body lean tissue estimates, 193 although there are only a few equations that have been proposed to predict FFM 194, 195 or skeletal muscle mass 196, 197 using the sum of thicknesses from 3-9 anatomical sites in healthy individuals. For a more complete discussion and review of the available validation literature on ultrasound for lean tissue assessment, the reader is referred elsewhere. 198 Generally speaking, ultrasound involves the transduction of high-frequency sound waves through the skin; the ultrasound beam is partially reflected back (as an echo) to the transducer from the interface of different underlying tissues (eg, subcutaneous adipose and skeletal muscle). 29, 186 How much the tissue reflects is expressed as acoustic impedance, and this ranges from the lowest acoustic impedance levels associated with air to the highest acoustic impedance values associated with bone tissue. 29 The best image quality is observed with the highest acoustic impedance values. 186 As the transducer receives the reflected beam, the echo is converted into electric signals and a 2-dimensional image is formed. 29 The scanning procedure itself is deceptively simple; the difficulties arise when it comes to interpreting the image to determine muscle thickness at the site(s) of measurement. The interface between adipose tissue and muscle can be difficult to differentiate, because the acoustic impedance of these tissues is somewhat similar, and they produce a weaker echo compared with one that would include interface with bone tissue. 29 One must identify the tissue boundaries and then measure the thickness of muscle using the electronic calipers that are standard with most systems; boundary identification is somewhat subjective and can lead to interrater errors.
In addition, ultrasound measurements of muscle may be made with the muscle in the contracted or relaxed state, in the standing or supine position. 198, 199 For most clinical settings, the individual will likely be in the supine position and the muscle will be relaxed; in the relaxed state, muscle tissue is compressible. 199 There is not yet consensus on the optimal protocol to follow in terms of the degree of pressure to apply when taking a measurement in the supine, relaxed position. Most published studies have used no or minimal 191, 193, [195] [196] [197] [200] [201] [202] [203] [204] tissue compression, but one recent report used maximal 205 compression. Although maximal pressure has been advocated as a way to counter the problem of edema interfering with measurements in clinical populations, 205 it has also been suggested that minimal or no compression may better allow for the identification and perhaps even quantification of edema, as has been observed in measures of the anterior thigh muscle thickness. 189 However, the application of no/minimal transducer compression on the muscle tissue may actually reduce the ability to detect small lean tissue changes in the presence of edema and/or adipose stranding. Furthermore, the no/ minimal pressure approach in individuals with obesity will quite likely be ineffectual in visualizing full tissue thickness and reference bone because of shear limb thickness exceeding ultrasound depth capabilities. On the other hand, with maximal compression, the degree of muscle compressibility and presence of edema may contribute to error, 29, 199 and the degree of pressure placed on the transducer against the skin is difficult to control to standardize measurements, making reproducibility difficult to achieve for longitudinal measurements. Maximal vs no/minimal transducer force will yield quite different muscle thickness measures, although this has not yet been well studied. In the adipose ultrasound literature, it was observed that the use of maximal transducer force reduced the measurements of subcutaneous adipose thickness by 24%-37% compared with minimal transducer force. 206 These are vitally important issues that need to be resolved so that consensus on protocol can be reached and appropriate reference data can be generated for use in clinical populations. A limited number of studies that have investigated the validity of ultrasound for quantifying muscle mass are relevant to the clinical setting. Ultrasound measurements of the biceps, forearm, and midthigh muscles (degree of transducer force was not described) were shown to correlate reasonably well (r = .872; P < .001) with LST measured by DXA in individuals with multiple-organ failure. 189 The intraobserver variability for midthigh measurements was observed to be 2.3% (CV), and the interobserver CV for the midthigh was observed to be 4.3%. In another study, the thickness of the quadriceps femoris muscle was negatively correlated with length of stay in individuals in the ICU; interrater CV was observed to be 1.3% using no/minimal compression. 190 Ultrasound of the quadriceps muscle using no/minimal compression has been shown to correlate well with quadriceps muscle strength in individuals with chronic obstructive pulmonary disease 203 and has also been shown to correlate reasonably well (r = 0.78; no P value provided) with MRI measurements in healthy individuals undergoing a bedrest study. 200 Two recent studies have evaluated the reliability and reproducibility of ultrasound measurements of the quadriceps muscle thickness in the setting of critical illness. 191, 205 Following a maximal compression protocol 207 (see Figures 7 and 8 ), Tillquist et al 205 reported good intrarater (average ICC = 0.98 with between-subject variance of 0.26 and within-subject variance of .005) and interrater (average ICC = 0.95 with betweensubject variance of 0.26 and within-subject variance of 0.015) reliability, with average muscle thicknesses for the left and right leg of 2.01 ± 0.52 cm for trainer 1, 2.0 ± 0.50 cm for trainer 2, and 2.09 ± 0.52 cm for the trainee. More recently, following a minimal compression protocol, another group reported excellent intrarater CVs of 1.91% and 1.32% with absolute variability expressed as the limits of agreement of 0.33 and 0.12 cm for operators 1 and 2, respectively. The absolute median interrater variability was 0.05 cm, with an ICC of 0.99 for single measurements; the mean muscle thickness over 86 duplicate measurements for the 14 participants was 2.10 ± 0.85 cm.
Ultrasound holds great promise, given its portability, relatively low cost, noninvasiveness, and clinical availability; ultrasound devices are prolifically abundant in ICUs and other units of most hospitals, and it takes less than 15 minutes to complete a measurement. Further research is needed to develop consensus on the optimal way to conduct ultrasound measurements to assess lean tissue with minimal error in clinical populations where edema, adipose stranding within muscle, and obesity in general are important considerations. The optimal site(s) for ultrasound measurement, the level of compression force to minimize error (ie, maximal vs no or minimal compression), and the optimal application of the muscle thickness measures for lean tissue assessment have yet to be established; furthermore, the use of simple muscle thickness measurements alone or the application of these measurements to equations to generate wholebody lean tissue values will certainly require the generation of population-specific reference data for their interpretation. Finally, once consensus on optimal protocol is reached and reference data are generated, additional research is needed to evaluate the role of ultrasound in bedside assessment of lean tissue and diagnosis of malnutrition in the hospital setting.
Applications to Clinical Case Scenarios
Scenario 1
A 67-year-old African American man is admitted to the hospital after experiencing a fall at home. He is diagnosed with a hip fracture. He admits to not eating very well over the past 6 months but is not sure if he has lost any weight. He has noticed that he is having difficulty taking care of chores around the house and is slower getting out of his chair than usual. No visible signs of muscle or fat loss are evident upon examination. is not yet standard practice, and there is a need for additional research to clearly establish how bioimpedance and/or ultrasound measurements might uniquely contribute to the assessment of nutrition status in the hospital setting, particularly in terms of what they tell us about muscle mass, we can • Obtain access to a portable ultrasound machine that uses a high frequency linear transducer.
• Obtain access to a flexible tape measure.
•
Have the patient lay supine with the knees extended and relaxed.
• Locate the top of the patella and the anterior superior iliac spine (ASIS).
Identify two points for measurements of the quadriceps femoris muscle (see Figure 8A ):
o Reading #1 will be taken at the border between the lower third and upper two thirds of the ASIS and the upper pole of the patella. o Reading #2 will be taken at the midpoint between the ASIS and the upper pole of the patella. o Note: In individuals with obesity, it may be very difficult to locate the ASIS. In such cases, note the distance from the upper border of the patella for all subsequent measures to be sure you are consistently coming back to the same place.
• Apply a generous amount of ultrasound gel to the area of the thigh that is to be evaluated.
Use a large (5 mHz) ultrasound probe and hold the probe perpendicular to the skin.
Start at maximum depth to identify the femur. Use the depth button to set the electronic focus depth at the shallowest depth allowable to see the femur.
Set the frequency at maximum allowable frequency.
For taking a measurement using maximal compression: Compress the probe maximally to measure muscle thickness directly anterior to the shaft of the femur.
For taking a measurement using no compression: Position the scanning probe on the skin surface at the area of the thigh to be evaluated, and visualize the femur without compressing the skin. In individuals with excessive adiposity, it may not be possible to use no compression. 195 In that event, attempt to compress the tissue only as needed to visualize the femur, and gradually reduce the pressure until the outer margins of the femur are no longer visible before taking the measurement.
• Muscle measurement should include the area anterior to the femur and proximal to the adipose tissue.
• Take readings at the two points as described above (see Figure 8B ):
o Measurement (roller ball or cursor); highlight caliper on screen. o Mark depth @ surface of femur (press Set).  Make sure measurement line is perpendicular.
o Mark proximal depth of muscle (press Set) up the fascia below the adipose tissue. o Check top left of screen for measurements.
Repeat the measurement for the other thigh, and then repeat the entire process on both sides; average the measurements and record for longitudinal tracking. hypothetically consider how these data might be used in a particular clinical case. Interpretation: Referring to Table 1 , we can compare our calculated values with the SMI by published SF-BIA cutpoints, recognizing the limitations of applying it in this way. Assuming for the moment that this has been validated for assessing muscle loss at the bedside, based on the SMI (height) cutpoint, his value of 11 kg/m 2 would not suggest that he is sarcopenic, although he is not far from the 10.75 cutpoint for moderate risk of disability based on that method. Based on the SMI (%weight) cutpoint, his value of 30% does suggest that he may be sarcopenic, given that values <31% indicate class II sarcopenia. Given that he has been having difficulty with activities of daily living, this information could be considered corroborative of some degree of muscle loss and/or nutrition compromise.
Using bioimpedance
Evaluate his PA:
Interpretation: To interpret PA, it is most appropriate to use reference data generated from a population that most closely resembles your patient in terms of ethnic background and other attributes. Ideally, we would like to have PA reference cutpoints generated by the same device that we are using and from an American reference population such as NHANES. Given that we do not currently have NHANES PA data available, the best option we have is the reference data generated in American individuals published by Barbosa-Silva et al. 139 Referring to Table 3 , we can compare his value of 4.1 with the non-BMI-specific cutpoint of 5.4, corresponding to the fifth percentile value for 60-to 69-year-olds (who were overweight on average). By these criteria, he has a low PA, which could indicate malnutrition. For the purposes of this hypothetical exercise, given the very high BMI of our patient, we might also look at the Bosy-Westphal et al 138 BMI-specific reference cutpoint representing the fifth percentile value for 60-to 69-yearolds, with BMI between 35.1 and 40, which is 4.7. Based on this cutpoint, we would also conclude that he has a low PA and may have some degree of malnutrition, although it may not be appropriate to apply the German white population cutpoints to our African American patient. We can also calculate his SPA. Referring to 174 and values >0.78 with increasing odds of having malnutrition. 171 In that light, we might reasonably interpret this value as corroborative of the other bioimpedance data that we have, in that it could indicate nutrition compromise and/or altered fluid status that could occur with lean tissue loss.
Putting all the bioimpedance data together, along with this patient's history of altered functional status, we might conclude that he has at least some degree of nutrition compromise and may in fact have sarcopenic obesity.
Using ultrasound
Quadriceps muscle thickness measured with maximal compression: 2.05 cm Quadriceps muscle thickness measured with minimal compression: 4.2 cm
Given that there is currently no consensus on the optimal protocol to follow to take an ultrasound measurement, and thus we do not yet have any reference data to draw from, at this point in time it is difficult to know how we might best use an ultrasound measurement in our patient. In the interest of this hypothetical case, however, we might consider using ultrasound measurements to track changes in lean tissue (through the measurement of quadriceps muscle thickness, following a consistent protocol) over time, after taking a baseline measurement upon admission. For the purposes of illustration, you can see that when we used a maximal compression protocol, his quadriceps muscle thickness was 2.05 cm, compared with 4.2 cm when we applied minimal compression. Thus, it is vitally important that we use the same protocol for follow-up measurements if we want to track muscle changes. At this point, our measurements cannot be easily interpreted because we have no reference data for either method, but we will remeasure the quadriceps muscle thickness every week while he is in the hospital to monitor, following consistent protocol.
Scenario 2
A 51-year-old white woman of European descent is receiving outpatient chemotherapy in combination with radiation therapy for the treatment of throat cancer. She is in her fourth week of treatment. Her intake has been quite poor, and she complains of sores in her mouth. She is generally fatigued and tires easily on exertion. She has stopped her daily walks (since the first week of treatment) and now tries to keep activity to the minimum necessary to get by. She has lost weight since starting treatment, although she is not certain how much. She appears to have some loss of fat from the orbital area but does not exhibit any other notable signs of muscle or fat loss upon physical examination. Interpretation: Referring to Table 1 , we can compare our calculated values with the SMI by SF-BIA cutpoints, with the same reservations as previously discussed. For the purposes of this exercise, based on the SMI (height) cutpoint, her value of 9.4 kg/m 2 does not suggest that she is sarcopenic. Based on the SMI (%weight) cutpoint, her value of 34.6% also does not suggest sarcopenia.
Evaluate her PA:
Interpretation: Referring to Table 3 , we can compare her value of 2.2 with the non-BMI-specific cutpoint of 5.5, corresponding to the fifth percentile value for 50-to 59-year-olds (who were overweight on average). By these criteria, she has a low PA, which could indicate malnutrition. For the purposes of this hypothetical exercise, given the BMI and white ethnicity of our patient, we might also look at the Bosy-Westphal et al 138 BMIspecific reference cutpoint representing the fifth percentile value for 50-to 59-year-olds, with BMI between 25.1 and 30, which is 4.9. Based on this cutpoint, we would also conclude that she has a low PA and may have some degree of malnutrition. We can also calculate her SPA. 171 Given what has been observed in the literature with impedance ratios above this cutpoint, our patient's value of 0.92 could be interpreted as suggesting altered nutrition status and/or altered hydration status.
Taken together, the bioimpedance data could be interpreted to indicate that this patient has at least some degree of muscle loss and/or nutrition compromise.
Using ultrasound
Quadriceps muscle thickness measured with maximal compression: 1.7 cm Quadriceps muscle thickness measured with minimal compression: 2.8 cm
In this individual, we measured a quadriceps muscle thickness using maximal compression of 1.7 cm and 2.8 cm using minimal compression. As mentioned in the first case scenario, we do not currently have appropriate reference data to interpret this cross-sectional measurement at this point in time, but we could monitor our patient weekly to observe for any changes, following a consistent protocol.
What about using bioimpedance or ultrasound to generate whole-body lean tissue estimates at the bedside? Generally speaking, it is not easy to know how best to obtain an accurate measure of whole-body FFM, BCM, or LST. At present, we do not have validated equations for predicting whole-body lean mass from ultrasound-measured quadriceps thickness. With regard to bioimpedance techniques, if we have access to a BIS device, we could consider generating the "normally hydrated lean tissue" (assuming we have a device that has appropriate software to model the data and calculate it from ECW and ICW values generated from the BMI-modified Xitron-Hanai-based mixture equations). Absolute accuracy of whole-body lean tissue measurements is less critical if we are interested in monitoring changes over time, although small changes may not be detectable given conservative estimates of 3%-8% MDC for bioimpedance techniques. It is important to recognize that all body composition measurement involves some degree of error due to biological variation and measurement error caused by protocol violations and human error, as well as device-and equation-specific error. If we wish to use our SF-BIA or MF-BIA device to evaluate whole-body lean tissue, we can refer to published sources 78, 96, 104 and, if needed, search the literature to find a population-specific, validated equation appropriate for the individual we wish to assess, to calculate FFM, BCM, or LST; however, this is not always an easy task, and whole-body estimates are difficult to interpret, given potential violations of underlying assumptions, particularly in acute illness. If we choose to evaluate whole-body measures, our best option is to use the same device with the same predictive equation and standardize the testing conditions as much as possible for longitudinal measures (see Table 2 ) to minimize error.
Caution regarding interpretation
• We must exercise extreme caution when interpreting whole-body values coming from a device that does not provide the source of the equation used to predict the values or from a known equation that does not well match the characteristics of our patient.
• Note that we do not apply reference cutpoints generated by one bioimpedance or reference method to interpret a body composition compartment or bioimpedance parameter measured by a completely different method (eg, do not use the Geneva equation-generated FFMI reference cutpoints to evaluate your patient's segmental MF-BIA-generated FFM value).
• We should understand that the interpretation of these various bioimpedance parameters, including PA, impedance ratio, SMI, and FFMI, is subject to the limitations of available reference data, the potential error caused by device-specific and population variable-specific differences between the various research laboratories producing them, and the lack of clarity over exactly what is being measured by these parameters. We must interpret findings in light of other clinical data at our disposal to build the most complete picture that we can of our patient's nutrition status.
Summary and Call to Action: Future Research Needs
Because of the key role that the body's lean tissue reserves play in the response to injury and illness, it is central to the maintenance of good nutrition status; this concept has been incorporated into the diagnostic criteria for malnutrition developed by AND and A.S.P.E.N. 15 Clearly, given the implications that the loss of lean tissue has on clinical outcomes in acute and chronic illness, its assessment is of critical importance to the nutrition field. Our ability to measure lean tissue at the bedside has been limited by the lack of available methods that can be considered sufficiently accurate for whole-body lean tissue estimates in the clinical setting, although absolute accuracy may not be the only consideration in the application of bedside techniques as monitoring tools. Many have advocated the use of subjective physical examination techniques to evaluate muscle loss in the clinical setting. The application of these more subjective techniques is likely to be limited by lack of precision and sensitivity, although research is needed to validate nutrition-focused physical examination techniques (applied using standardized training protocols) against more objective measures. To identify muscle loss in a severely cachectic individual through nutrition-focused physical examination techniques 16 is likely to be far less challenging than it would be in an overweight individual dealing with acute or chronic illness. Indeed, the detection of sarcopenia in the presence of overweight or obesity presents a significant and important challenge to the assessment of malnutrition today and is likely to require objective measurement techniques (eg, CT, as observed in the recent study by Sheean et al 19 ). Whether or not existing bedside techniques (eg, bioimpedance and ultrasound) can be used to routinely evaluate lean tissue loss (and thus nutrition status) in the clinical setting remains to be determined.
It is hoped that through this tutorial, the reader has gained an appreciation for the complexities involved in the validation of bedside body composition assessment methods and for the different ways that bioimpedance data are generated and applied. There is substantial and growing interest worldwide in the potential utility of simple bioimpedance variables to identify malnutrition, apart from the estimation of whole-body lean tissue compartments that have sometimes yielded wide variation in individual measures compared with reference methods, particularly in individuals with extreme obesity and other populations where assumptions may be violated. Although these violations are likely to yield some degree of error in the bioimpedance measurements, the precision (ie, from repeated measurements) of the reference method is not always evaluated in research studies, particularly those using dilution methods; lower precision in the reference method could contribute error to the methods comparison that may be inadvertently interpreted as solely coming from the bioimpedance method. A consensus on how best to evaluate the validity of a bedside method in terms of limits of agreement PE and measurement error in light of reference method precision (among other possible criteria) needs to be reached. Further refinements of the BIS technique as applied in the dialysis population 184 to quantify "excess fluid" may yield improvements in the "normally hydrated lean tissue" wholebody estimates; in that event, reference data would need to be generated and made available. SMI by the Janssen equation, 137 FFMI by the Geneva equation, 135 and FFM by the Chumlea NHANES III equation 98 are perhaps the best candidates for equations that could be cross-validated from the most recent NHANES data; reference data could be generated from NHANES for those equations proven to be most valid to provide useful cutpoints for sarcopenia based on American population data, ideally by BMI, age, and ethnicity. Similarly, reference data for the 50-kHz PA and 200/5-kHz (and also Z ∞ /Z 0 if available) impedance ratio could be generated from the most recent NHANES data set. For raw bioimpedance parameters to be useful at the bedside, a consensus on normal reference values and cutpoints to define sarcopenia and/or malnutrition is needed to facilitate interpretation; this may require bioimpedance device companies to come together to somehow cross-calibrate and/or streamline technologies. In addition, recent developments in the ultrasound field are making that method an attractive option for bedside nutrition assessment. It will need additional refinement in terms of standardizing measurement protocols to minimize inter-and intraobserver errors so that good precision can be consistently achieved. In addition, reference values for normal muscle thickness as well as cutpoints to define sarcopenia will need to be established. How well ultrasound and/or any of the available bioimpedance techniques can contribute to nutrition assessment at the bedside (to produce whole-body estimates of lean tissue, to identify muscle loss [ie, sarcopenia], and/or to produce useful markers of malnutrition) is a vitally important question that remains to be answered.
Call to Action
The global clinical nutrition community needs to work together to come to consensus on the optimal tool(s) to use to assess nutrition status at the bedside. Clinician researchers who are interested in validating the AND/A.S.P.E.N. consensus malnutrition diagnostic criteria should strive to include at least one reference technique for lean tissue (eg, CT and/ or DXA) to validate the subjective nutrition-focused physical examination method of evaluating muscle loss. In addition, at least one and ideally both of the currently available bedside techniques, ultrasound and bioimpedance (eg, an MF-BIA and/or BIS device can produce PA and an impedance ratio; a BIS device appropriate to provide whole-body "normally hydrated lean tissue" and other whole-body estimates in addition to the simpler raw BIA parameters would have added benefit) should be used in the same study to evaluate their ability to contribute uniquely to the identification of lean tissue loss and malnutrition. Collaboration and open sharing of data among researchers and cooperation between device manufacturers to streamline technologies and facilitate the production of normal reference data would allow for greater progress.
Two key questions that must be answered are:
1. Can a standardized subjective nutrition-focused physical examination method accurately detect muscle loss in individuals across the acute/chronic illness and weight spectrum compared with objective reference measures (eg, CT, DXA)? 2. In these same clinical populations, can ultrasound or a particular bioimpedance approach help us to identify and monitor subtle changes in lean tissue (and thus nutrition status) compared with reference measures that would not have otherwise been possible through other, more subjective assessment methods?
